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Melanoma, a tumour of the skin, has exceptionally high mortality rates, claiming 
approximately 350 people every year within New Zealand. This makes melanoma the fourth 
most common cause of cancer-related deaths within the country, indicating a need for better 
treatments to improve patient outcomes. Anti-PD1 immunotherapy (e.g., Pembrolizumab) 
targets and stimulates suppressed cytotoxic T cells to eliminate the cancer. However, long term 
efficacy remains low and immune-related adverse events (irAEs) remain frequent. 
 
Previous research in our laboratory using a murine model showed that ascorbate 
supplementation modifies tumour-associated Macrophages (TAM) into a population of 
macrophages that have neither definitive inflammatory (M1-like) or anti-inflammatory (M2-
like) phenotypes. These changes in gene and protein expression could exert either pro- or anti-
tumour effects and potentially mediate phenotypical change that affects anti-tumour immunity, 
as well as the chronic inflammatory cascade induced by immunotherapy that underlies many 
irAEs. Interestingly, ascorbate supplementation can enhance activity of epigenetic modifiers 
within immune cells, including Ten-eleven Translocation 2 (TET2), which has been suggested 
to simultaneously support and limit cancer progression. The aim of this study was to establish 
an in-vitro model to study the effects of melanoma cells on monocytes/macrophage phenotype 
and function, and to answer the following questions: 1) Can ascorbate supplementation alter 
TAM phenotype in a human model and 2) Does ascorbate supplementation alter TET2 activity 
in these macrophages. 
 
To address these questions, relevant markers were measured after monocytes were cultured in 
melanoma cell line NZM40-derived condition media (20%) for 7 days, with or without 
ascorbate supplementation (100𝜇M). Quantitative PCR was used to determine relative gene 
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expression of TAM related genes. Immunocytochemistry and high-throughput imaging were 
used to identify and quantify M1- and M2-affiliated phenotypic cell surface markers, HLADR 
and CD206, respectively. Mass Spectrometry was used to assay the epigenetic marker 5-
hydroxymethylcytosine, indicative of TET2 activity. These experiments demonstrated that 
NZM40-derived condition media supported monocyte growth, but did not stimulate gene 
expression and surface marker presence expected of M2-like TAMs. Rather, it generated 
Macrophage populations that were of mixed M1- and M2-like phenotype. When compared to 
NZM40-derived condition media alone, ascorbate supplementation enhanced TET2 activity 
(as evidenced by the increase DNA demethylation) and increased the presence of the M1 
surface marker, HLADR, but did not induce significant changes in gene expression. 
 
This study provided some evidence to support the concept that ascorbate supplementation alters 
TET2 activity and TAM phenotype. However, this study also highlighted the limitations of the 
in vitro model used, and future studies would aim to develop a co-culture model for bi-
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Chapter 1 - Introduction: 
 
1.1.  Melanoma in New Zealand 
Currently, malignant neoplasms are one of the leading causes of premature mortality in the 
western world. Neoplasms are a collection of cells that possess accumulated epigenic and 
genomic alterations that allow for enhanced proliferation and survival. Commonly referred to 
as tumours, neoplasms can be categorized as either malignant (cancerous) or benign, depending 
on the cells invasive or non-invasive characteristics, respectively. (1) Melanoma is a form of 
skin tumour, arising from melanocytes found in the epidermal basal layer of the skin. 
Melanocytes offer protection from UV radiation through the production of melanin, a 
necessary mechanism for minimizing cellular genomic damage. (2) However, with the 
accumulation of genomic abnormalities, melanocytes can become tumourigenic (3).  
 
With a large mutational burden, melanomas are frequently found to be associated with poorer 
patient outcome (2, 4). Although accounting for only 4% of skin cancer cases in the US, 
melanoma is responsible for 75% of skin cancer-associated deaths. (2) Within New Zealand, 
melanoma is the third most common form of tumour, with approximately 2,200 people being 
diagnosed and ~350 patients dying annually, predominately from metastatic melanoma (5). In 
comparison to other countries, New Zealand has a particularly high incidence rate of melanoma 
- 35.1 per 100,000 people compared to 22.1 per 100,000 in the US (2, 5). This produces one of 
the highest cancer incidence rates in New Zealand, second only to colorectal cancer. (5) A 
contributing factor to New Zealand’s incidence rate is the country’s ultraviolet radiation (UV) 
exposure, receiving approximately 40% more UV than northern hemisphere latitude 
counterparts (6). As UV is a casual factor towards genomic damage, the country’s exposure 
rate acts as a risk factor for melanoma development (7). Currently, melanoma treatment 
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comprises of surgical resection, immunotherapy, chemotherapy and photodynamic therapy (3). 
However, with varied efficacy and toxicity to patients, further research and development of 
therapies is still required (8, 9).    
 
1.1.1.  Immunotherapies and Cancer  
With a high mutation rate, melanomas are highly immunogenic, producing numerous tumour 
antigens. However, efficient immunity is limited by the tumour’s capacity to escape the host 
immune response. (2) Immune evasion can exist in several forms, including enhanced 
expression of immune checkpoint molecules, stimulation of immune regulators, and selection 
of immune resistant neoplasms (2, 10). With the expression of immune checkpoint proteins, 
such as programmed cell death protein ligand 1/2 (PD-L1/2), tumours can directly dampen 
ongoing immune responses. PD-L1/2 are immunoregulatory surface proteins that interact with 
PD-1 expressed on T cells. (2) Upon interaction, T cell exhaustion and anergy is induced, 
reducing proliferation and functionality of T cells, stimulating T cell apoptosis and 
downregulating the adaptive immune response. (11, 12) In addition, tumours can express 
immune suppressive cytokines and chemokines, attracting, stimulating and generating in-situ  
regulatory T cells (Tregs) (10, 13). Tregs expression of immunosuppressive cytokines, e.g., IL-
10 and CTLA-4, can hinder the anti-tumour immune responses (14). Alongside Tregs, 
myeloid-derived suppressor cells (MDSC) and Dendritic cells (DC) can be modulated by 
tumours, further enhancing T cell suppression. Moreover, through ongoing clonal selection, 
tumours can directly evade the immune system. Pro-tumour phenotypes may arise with 
downregulated T cell costimulatory molecules, death receptors and antigen presenting 
machinery, preventing activation of an immune response. (10) Together, these mechanisms 




As a result of the tumour’s capability to evade the immune system, immunotherapies have been 
designed to elevate or suppress tumour-associated immunity. These novel treatments can be 
categorized into three forms; immune checkpoint therapy, adoptive T cell transfer, and 
vaccination. Predominately, immune checkpoint therapy comprises of CTLA4 and PDL1 
antibody blockades. (8) CTLA4 is a immunoregulatory protein expressed by Tregs, functioning 
to hinder the stimulatory signals necessary for T cell activation (15). By recognizing the 
immunosuppressive role of CTLA4, antibodies against CTLA4 have been developed, with 
Ipilimumab, an IgGk monoclonal antibody, being approved by the FDA for clinical treatment 
(8). Consequently, 22% of advanced melanoma patients gained a 3-year survival benefit 
through the use of Ipilimumab (16). However, this was not always replicable. With lower 
tumour immunogenicity and larger tumour burdens, anti-CTLA4 therapy efficacy was reduced. 
Similar to CTLA4, antibody-based therapies against PD-1/L1 arose in recognition of the 
proteins’ role in immunosuppression. Pembrolizumab, an IgG4-based anti-PD1 therapy that is 
used predominately in Christchurch hospital, New Zealand, has shown great promise in 
patients with advanced melanoma who previously had dismal outcomes (8, 17). However, only 
20-30% of patients show progression free survival (PFS) after 5-years of treatment (18). Anti-
PD1 therapies can be dependent on neoantigen load and presence of PD-L1, with reduced 
mutational burden and PD-L1 expression being correlated with decreased response (8, 19). 
Moreover, immune checkpoint therapies are associated with immune-related adverse events 
(irAEs). Currently, 15-90% of patients are estimated to experience a form of adverse event 
from checkpoint therapy, with 15% and 30% of these patients, treated with anti-PD1 and anti-
CTLA4, respectively, suffering from severe irAEs (grade 3+). Typically, toxicity has been 
reported to arise from overreactive memory T cells and a reduction in naïve T cells, resulting 
in organ-tissue damage. Therefore, while checkpoint therapies have improved survival, 




A common cause of irAEs is the inflammatory cascade triggered by the immunotherapy. 
Inflammatory toxicities can range from dermatitis, commonly treatable, to organ dysfunction, 
alongside neurologic and endocrine toxicity, which can lead to considerable morbidity and 
mortality. Using colitis development as an example, the administration of checkpoint 
immunotherapies releases residential T cells that react with organisms from the microbiome, 
allowing expansion and upregulation of inflammatory cytokines into the colon environment. 
With enhanced recruitment of T cells and an escalating inflammatory response, colitis develops 
in the patient. (20) Moreover, while its affect is pleiotropic, chronic inflammation can 
simultaneously stimulate the immune system and promote carcinogenesis (21). The 
development of inflammatory toxicities can lead to the discontinuation or delay of 
immunotherapy, reducing the capabilities of the treatment (20). Thus, indicating the need for 
further research and development of therapies that continue to stimulate the immune system 
without inducing a systemic inflammatory cascade.   
 
1.2.  Tumours and the Surrounding Microenvironment 
1.2.1. The Changing Tumour Microenvironment 
The tumour microenvironment consists of an interacting network of mesenchymal cells, lymph 
and blood vessels, immune cells, fibroblasts and extracellular matrix, which co-exist with the 
transformed cancer cells. (22) Adding to this complexity, the tumour microenvironment is 
hostage to temporal and spatial heterogeneity of transformed cells, responding to fluctuating 
stimuli (23, 24). Such temporal and spatial heterogeneity describe phenotypical differences of 
transformed cells over time, or across a population at a singular time point, respectively (24, 
25). Together, this allows for immune evasion, therapy resistance and ongoing carcinogenesis, 
eliciting further challenges towards cancer treatment (2, 26). These challenges help to highlight 
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the advantages of immunotherapy, as the immune system is a dynamic mechanism that can 
modify its response as transformed cells change.      
 
1.2.2. Immune Tumour Microenvironment  
The immune tumour microenvironment comprises of a complex interplay between the tumour 
and immune cells, depicted in figure 1.1 (10). The relationship between these systems creates 
a dynamic environment of cell death and proliferation, fluctuating with a destructive or 
suppressive immune response (22). Initially, development of an inflammatory response serves 
to hinder tumour progression, however, over time a chronic inflammatory microenvironment 
may serve to enhance tumourigenesis. Thus, highlighting the complexity the immune tumour 
microenvironment may impose on the host immune response to cancer. (10)      
      









Figure 1.1: The Complex Interplay Between the Tumour, Immune System and Tumour 
Microenvironment. An interacting environment of immune cells, tumour cells, cancer stem 
cells (CSCs), pericytes, epithelial cells, endothelial cells and blood vessels, is depicted.    
Adapted from Joyce, J.A. and J.W. Pollard, licensed under Creative Commons Attribution 3.0 




The complex relationship between the tumour and the immune system gives rise to three 
possible outcomes; elimination, equilibrium and escape, a process referred to as 
immunoediting. Initially, if the anti-tumour response is sufficient and effective, the immune 
system will successfully recognize and eliminate transformed cells. However, with the 
emergence of immunogenic heterogeneity over clonal generations, some cells may evade 
immune surveillance. In turn, a balance between elimination and evasion may form, enacting 
a state referred to as equilibrium. In this state, transformed cells continue to accumulate 
genomic alterations, while the tumour’s size is still limited by the immune system. However, 
with time, a tumour may acquire the necessary characteristics to overcome the anti-tumour 
response, allowing it to escape and become a clinically apparent tumour. (10)  
 
Within the tumour immune response, two key groups of cells exist, lymphocytes and innate 
cells, both capable of contributing immunoregulatory and/or effector responses according to 
immune cell plasticity, a characteristic that enables phenotypic alteration in response to 
environmental cues (28-31). Under physiological conditions, such immune cell plasticity 
allows for dynamic modulation of pathogen destruction, resolution of the inflammation 
response, and host tissue healing (28, 32).   
 
1.2.2.1.  Lymphocytes within the Tumour Microenvironment 
As tumourigenesis progresses, lymphocytes become a key contributor to the elimination of 
transformed cells. Comprising of several subsets, the cells can be categorized into T cells, B 
cells and innate lymphocytes consisting of Natural killer T cells, Natural killer cells and 𝛾𝛿 T 
cells (29, 30). However, different lymphocyte subsets can have opposing roles within the 
tumour microenvironment (14, 33). For example, cytotoxic CD8+ T cells primary function 
encompasses the killing of transformed cells, either by releasing apoptosis-stimulating granules 
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after inducing pore formation, or acting through the stimulation of death domains by Fas 
interaction. (33) In contrast, Tregs elicit immunosuppression through mechanisms such as 
CTLA4 expression, growth factor competition and immunoregulatory cytokine secretion, i.e., 
IL-10 (14). Therefore, as the number, type, and activity of lymphocytes within the tumour 
microenvironment impact patient outcome, the cells remain the focus of international research 
and ongoing therapy development (29, 34).   
 
1.2.2.2.  Innate Cells within the Tumour Microenvironment 
Through immunosurveillance, innate cells act as the first responders to tumour development, 
serving to eliminate the transformed cells and help evoke an adaptive immune response (30, 
35). These cells can be categorized into myeloid-derived cells and DCs (30, 36). Myeloid-
derived cells comprise of monocytes, megakaryocytes, mast cells, eosinophils, neutrophils, 
erythrocytes, MDSCs and basophils, sharing a common progenitor, myeloid stem cells (30, 
37). In contrast, DCs can derive from myeloid and lymphoid progenitors (36). Similar to 
lymphocytes, different innate cells and their subsets can have opposing roles in the tumour 
microenvironment (29, 37). For example, MDSCs can be considered as pro-tumourigenic, as 
the cells can interfere with ongoing immunity through the expression of CTLA4, IL10, PD-L1 
and TGF-𝛽, impairment of T cell trafficking, Treg recruitment and suppression of developing 
B cells (37). Comparatively, CD8𝛼+ DCs have been associated with CD8+ T cell priming, 
through presentation of tumorigenic antigens, and production of type I interferons (29). Despite 
the important role of innate cells in tumour immunity, these cells are often overlooked during 






1.3.  Monocytes/Macrophages  
Macrophages (Mϕ) are innate cells of dynamic functionality - from the phagocytosis of foreign 
pathogens, to the orchestration of tissue repair (31). Within the tumour microenvironment this 
does not alter, with Mϕ being associated with angiogenesis, cell invasion and immune 
suppression, along with the presentation of tumour antigens, tumoricidal species generation 
and pro-inflammatory cytokine secretion (38, 39). With such dynamic functionality, Mϕ can 
be considered pro- and anti-tumorigenic cells depending on microenvironmental context (39).        
   
1.3.1.  Differentiation and plasticity of macrophages 
Differentiating from monocytes that arise from hematopoietic stem cells, or from embryogenic 
progenitors, Mϕ are plastic phagocytes that, for simplicity, can acquire classically activated 
(M1) or alternatively activated (M2) phenotypes, depending on the stimuli (40-42). 
Consequential to M1 Mϕ being found to produce ROS, present antigens and secrete IFN-𝛾, 
IL-12, and TNF-𝛼 cytokines, these Mϕ are dubbed pro-inflammatory. Comparatively, M2 Mϕ 
are associated with an anti-inflammatory phenotype, producing IL-10 and engaging in tissue 
remodeling. (38) While this simplistic nomenclature is widely used, M1 and M2 categorization 
fails to represent the extent of a phenotypical spectrum influenced by a continuum of stimuli 
and other underlying biological systems (43).  
 
Mϕ differentiation and plasticity are shaped by lineage-determining (LDTFs), and signal-
dependent transcription factors (SDTFs) (40, 44). Determining chromatin accessibility, LDTFs 
serve to define transcriptional programmes that drive cells towards particular cell types with 
specific functions. Building on this, SDTFs respond to specific stimuli, inducing regulatory 
programmes to adapt the cell’s phenotype accordingly. (44) Simultaneously, as differentiation 
occurs, unwanted promoters and enhancers are typically silenced by epigenetic markers, while 
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previously suppressed elements become activated by opposing mechanisms. For example, as a 
monocyte differentiates into a Mϕ, approximately 3000 enhancer regions are silenced, while 
6000 are activated. (40) Furthermore, such epigenetic mechanisms extend to plasticity, with 
epigenetic elements regulating enhancer and promoter repertoires as Mϕ adapt to stimuli (40, 
44). Together, these cascades work in conjunction, allowing for the observed differentiation 
and phenotypic plasticity (44).   
 
1.3.2. Tumour-associated macrophages 
During tumourigenesis, inflammatory monocytes, resident Mϕ and immature monocytes are 
recruited into the tumour microenvironment (38, 45). Driven by immunosuppressive cues, such 
as tumour-derived lactic acid and immunoregulatory cytokines, the recruited cells can 
differentiate into tumour-associated macrophages (TAMs) (38, 46, 47). Typically, TAMs 
possess a M2-like phenotype, being affiliated with the stimulation of proliferation and survival 
of transformed cells, along with the promotion of angiogenesis, immunosuppression, 
inflammation and chemotherapy resistance (38, 48). For example, with the production of 
VEGFA and IL-10, TAMs can promote angiogenesis and elicit immunosuppression, 
respectively, while through the expression of cytidine deaminase TAMs can offer protection 
against gemcitabine, a chemotherapeutic drug used in cancer therapy. (38, 49) However, 
exceptions to these roles can be found within melanoma, prostate and colorectal cancer, with 
TAMs serving a more protective role (50, 51).  Once more, this arises from M1/2 categorization 
limiting the representation of plasticity, with heterogenous TAM populations existing within a 
tumour. Depending on the microenvironment, TAMs have been associated with the production 
of chemokine factors such as MIP-1𝛼, an immature DC and T cell chemoattractant, and the 
induction of apoptosis and cytotoxicity in transformed cells (51). While previous research has 
elucidated many TAM expression profiles, more work is required to fully understand TAMs 
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genetic expression within different cancer types and microenvironmental contexts, and, how 
this corresponds to epigenetic and transcription programmes.     
 
To elucidate the phenotypical characteristics of the TAMs investigated in this study, a selection 
of genes and surface markers were analyzed. The following gene panel was measured:     
1) Mannose receptor C-type 1 (MRC1) – Encodes CD206, a transmembrane glycoprotein that 
scavengers mannoglycoproteins and is recognized as a M2 marker within humans (52, 53). 
The proteins exact functions in an immune setting remain unclear, but CD206 knockout 
has been associated with an upregulation of inflammatory cytokines and proteins, 
indicating a role in the anti-inflammatory response. Moreover, CD206+ Mϕs have been 
associated with collagen production, if the cells differentiate into a fibrocyte-like 
phenotype, suggesting that CD206 upregulation may be an early marker of wound healing. 
(52)  
2) Transforming growth factor beta 1 (TGF𝛽1) – Encodes for the secretory TGFβ1 ligand 
that has been designated a M2 lineage marker (54). The cytokine’s presence has been 
shown to regulate T cell expansion through inhibiting the upregulation of transferrin and 
IL-2 receptors, while hindering B cell proliferation and antibody secretion in a IL-2 
dependent and BCDF-dependent manner, respectively (55, 56). Moreover, NK cell’s 
function was found to be depressed by TGFβ1 triggering interferon-𝛼 receptor 
downregulation (57). TGFβ1 has also been demonstrated to enhance recruitment of 
myeloid-derived suppressor cells and promote metastasis, as the ligand has been associated 
with upregulation of chemokines and the epithelial to mesenchymal transition (EMT) (54).     
3) Interleukin 10 (IL10) – Encodes for the anti-inflammatory cytokine IL-10, a M2-affilated 
cytokine that exerts immunoregulatory affects (52, 58, 59). In brief, IL-10 can induce the 
expression of other anti-inflammatory cytokines, such as IL-27, along with decreasing 
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antigen presentation, stimulating cellular scavenger, immune tolerance and inhibitory 
functions, and, inhibiting phagocytosis and pro-inflammatory cytokine secretion. (58)          
4) Matrix Metalloproteinase 2 and 9 (MMP-2 and MMP-9) – Encodes for the extracellular 
proteinases MMP-2 and MMP-9, which degrade gelatin and type-IV collagen substrates 
(60). Both proteinases have been associated with immunostimulatory and 
immunosuppressive functions, facilitating the recruitment of immune cells into the 
necessary tissue, alongside the activation and deactivation of chemokines and cytokines. In 
particular MMP-2 has been associated with the degradation of monocyte chemoattractant 
protein-3 (MCP-3), while MMP-9 has been associated with enhanced activity of IL-8 and 
degradation of CD25, as well as the cleavage of other chemokines and cytokines. (61, 62) 
MMP-9 is typically associated with M2-lineage, while MMP-2 can be affiliated with M1-
like phenotypes (63).   
5) C-C motif chemokine ligand 3 (CCL-3) – Encodes for the CCL-3, an inflammatory 
cytokine that has been associated with M1-like Mϕ (64, 65). Previously, the cytokine has 
been found to increase the recruitment of lymphocytes, DCs and Mϕs into inflammatory 
tissue (65, 66). However, in some circumstance, CCL-3 has been found to contribute to 
immunosuppression, through upregulating the recruitment of TAMs, MDSCs and Tregs to 
the tumour environment (67).   
6) CD163 – Encodes for the haptoglobin-haemoglobin scavenger receptor CD163, an M2 
marker (52). While CD163 has been associated with the induction of inflammation during 
a bacterial infection, in a cancer setting, the protein has been linked with 
immunosuppression, e.g., hinderance in the production of proinflammatory cytokines from 
T cells (68-70).   
7) Ten-Eleven Translocation 2 (TET2) – Encodes for the multidomain dioxygenase TET2, 
which acts as an epigenetic eraser of DNA methylation, with the aid of its co-factors Fe(II) 
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and ascorbate, and co-substrates, alpha-ketoglutarate and oxygen (71-80). The removal 
of methyl markers increases the accessibility of promoters to transcriptional machinery, 
inducing gene expression (44).          
8) Tumour Necrosis Factor alpha (TNF𝛼) – Encodes for the pleiotropic cytokine TNF𝛼, 
which exerts both immunostimulatory and immunosuppressive activity, along with a range 
of other biological activity (81). For example, the cytokine has been linked with the 
development of B cell follicles, while being associated with the resolution of inflammation 
(82, 83).  Typically, TNF𝛼 is associated with M1-like Mϕ (59).  
9) Interlukein-1beta (IL-1𝛽) – Encodes for the pleiotropic cytokine IL-1𝛽, which has been 
associated with immunosuppressive and immunostimulatory activity (84-86). Previously, 
the cytokine has been strongly implicated as pro-inflammatory, promoting proliferation and 
differentiation of several immune cell lineages (85, 87). However, in some circumstances, 
IL-1𝛽 can aid in the resolution of inflammation through mechanisms such as the promotion 
of myeloid cell recruitment, but only limited evidence currently exists (86). Typically, IL-
1𝛽 has been affiliated with M1-like Mϕ (59, 88).         
 
The following surface marker panel was measured: 
1) CD14 – Marker of monocytes. Expressed highly on classical and intermediate monocytes, 
whereas non-classical monocytes express the surface marker at low levels. (89) CD14 
expression can also be found on Mϕs (90, 91).     
2) CD68 – Robust marker for the Mϕ lineage (66). CD68 expression can also be found on 
monocytes, but the surface markers expression has been found to upregulate during Mϕ 
differentiation (92, 93).   
3) CD206 – Coded for by MRC1 as detailed above.  
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4) Human leukocyte antigen DR (HLADR) – A class II MHC molecule isotype that presents 
antigens to lymphocytes, bridging the innate and adaptive immune systems (94, 95). 
HLADR has been associated as an M1 surface marker (96).       
 
1.4. Epigenetics Regulation of Macrophage Differentiation and Plasticity  
Mϕ plasticity is dependent on the epigenome, an epigenetic environment that allows for 
genetic expression fluctuation, without alteration to the genetic sequence (40). Typically, the 
genome exists as a hierarchically packed system, comprising of higher-order structures from 
topologically-associated domains to chromosomes (97, 98). At the basal level, nucleosome 
structures are generated through interacting DNA and histone proteins altering chromatin 
accessibility, as DNA elements can be excluded from transcriptional machinery (44, 99). To 
overcome such exclusions, epigenetic modifications can alter accessibility through binding to 
histone tails. Moreover, epigenetic elements can impact the activation or repression of DNA 
elements through directly hindering or increasing accessibility. Consequently, epigenetic 
modification serves as a key modulator of genetic expression, allowing for cellular 
differentiation and plasticity. (44)     
 
1.4.1. Epigenetic Mechanisms 
Epigenetic mechanisms exist in several forms, including histone modification, noncoding 
RNA, and DNA methylation. Post-translational histone modification comprises of methylation 
or acetylation of histone tails, altering the accessibility of DNA elements. Depending on the 
number and placement of methyl groups onto lysines present in histone tails, histone 
methylation can either induce repression or stimulation of gene expression. For example, H3K3 
trimethylation induces promoter activation, while H3K27me3 represses gene expression. 
Comparatively, acetylation of histone tails interferes with interactions between histones and 
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DNA through acetyl groups reducing lysine charges, resulting in the induction of gene 
expression. Alternatively, DNA methylation suppresses expression through the placement of 
methyl groups onto cytosines at CpG islands, blocking transcriptional machinery from 
accessing the sites. These functions are reliant on epigenetic writers’ capability to place methyl 
or acetyl groups onto the correct structures. However, as cells differentiate, epigenetic markers 
alter over time, indicating the need for epigenetic erasers. (40) 
 
1.4.2.  Ten-eleven Translocation 2 (TET2)  
Ten-eleven translocation 2 (TET2) serves as an epigenetic eraser for DNA methylation, 
removing methyl groups found on DNA (71, 72). TET2 is a multidomain dioxygenase, 
catalysing the demethylation of DNA with the aid of its cofactors Fe(II) and ascorbate, and co-
substrates, alpha-ketoglutarate and oxygen (73-80). Through interacting with 5-methylcytosine 
(5mC) present at CpG islands, the enzyme oxidizes the substrate into 5-
hydroxylmethylcytosine (5hmC), which can be subsequently oxidized into 5-formylcytosine 
(5fC), followed by 5-carboxylcytosine (5caC) (71, 72, 100). From these products, cytosine can 
either be excised and replaced by an unmethylated cytosine through base-excision repair 
pathways, or evade methylation maintenance during DNA replication, as DNMT1 poorly 
recognises 5hmC (101-104). The complete removal of methylation markers allows 
transcriptional machinery access to genes (40).  A schematic of TET2 pathway can be observed 
in figure 1.2. Similar to TET2, TET1 and TET3 function to demethylate DNA through the 
generation of 5hmC, 5fC and 5caC products (71, 76, 100). However, the TET enzymes do 










In a melanoma setting, TET2 within TAMs has been described as a tumour promoting enzyme, 
as it promotes an immunosuppressive environment (106). Previously, TET2 has been 
associated with the suppression of IL-6 (through HDAC2 recruitment) and TNF𝛼, both pro-
inflammatory cytokines (106, 107). Furthermore, using murine melanoma models, Pan and 
colleagues have found that through the IL-1R-MyD88 pathway, TET2 expression was 
enhanced within TAMs (106). In TAMs, TET2 was positively correlated with 
immunosuppressive gene expression and downregulation of pro-inflammatory genes, with the 
exception of the pro-inflammatory cytokine IL-1𝛽 (86, 106). The use of a myeloid TET2-
knockout murine model, also identified greater frequencies of CD4+ and CD8+ T cells within 
the tumour microenvironment, while the presence of Tregs decreased (106). However, it has 
recently been suggested that TET2 could reduce the negative regulation of JAK/STAT 
pathways, through removing the methyl groups on Socs3. In turn, this allows recognition by 
ADAR1, stimulating the degradation of the negative regulator. (108) With JAK/STAT 
pathways being affiliated with the induction of various pro-and anti-inflammatory genes, this 
suggests that TET2 may have a role in promoting inflammatory environments, alongside 
Figure 1.2: Schematic of TET2 Removing Methylation Markers from DNA. TET2 interacts and oxidizes 5-
methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), which can then be oxidized into 5-
formylcytosine (5fC), followed by 5-carboxylcytosine (5caC). From these products, complete demethylation 
can occur and transcriptional machinery can have access to the gene. Figure was created on BioRender.com    
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immunosuppression (109). Nevertheless, current evidence is limited, meriting further 
investigation (108).      
 
1.5.  Ascorbate and the Immune System 
 
Within the body, the micronutrient ascorbate (vitamin C) contributes to diverse functions of 
the immune system. The vitamin has been has been shown to act as an antioxidant, epithelial 
barrier supporter and enhancer of phagocytosis, apoptosis, chemotaxis, proliferation, 
differentiation and generation of ROS. (110) Typically, when plasma ascorbate concentrations 
are ≥50𝜇M, ascorbate within monocytes can be found at intracellular concentrations of ~3mM, 
a value that can be manipulated as sodium-ascorbate co-transporters, among others, enable 
active uptake of the micronutrient (110-116).  
 
Previously, Ang and colleagues, using a murine model, have identified ascorbate as a 
modulator of TAM phenotypes, changing gene and protein expression profiles to a phenotype 
that could exert a combined or either pro- (immunosuppressive) or anti-tumour 
(immunostimulatory) effect (45). Previously, stage IV melanoma patients, particularly those 
receiving immunotherapy, have been found to exhibit reduced plasma ascorbate 
concentrations. In light of Ang and colleagues study, and as higher grade melanomas are 
associated with reduced patient plasma ascorbate concentrations, this suggests that ascorbate 
may serve an important role in melanoma through modulating TAM phenotype (45, 117).              
 
1.5.1.  The Effect of Ascorbate on TET2 Function  
Ascorbate has been identified as a co-factor for dioxygenase enzymes, including TET2 and 
Jumonji containing histone demethylases (KDMs), functioning to recycle Fe3+ back to Fe2+ 
during enzymatic activity (73-75, 78, 116, 118, 119). A depiction of ascorbate acting as a TET2 
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co-factor can be observed in figure 1.2. Previously, ascorbate supplementation has been shown 
to heighten TET2 function (120, 121). Using a murine model, ascorbate supplementation 
enhanced TET2-dependent hypomethylation and downstream target gene expression (120). 
Agreeing with these results, Xu and colleagues found in a murine model that through TET2-
dependent mechanisms, ascorbate injection induced increased frequencies of tumour-
infiltrating T cells and enhanced expression of PD-L1, CXCL10, CXCL9, and CXCL11 (121). 
Moreover, Cimmino and colleagues demonstrated that with ascorbate supplementation, TET2 
activity can be restored when mutations or mono-allelic loss of the enzyme is present (120). 

















Research Questions, Hypotheses and Aims:  
Many irAEs arising from anti-PD1 immunotherapy are the result of a systemic inflammatory 
cascade, leading to autoimmune-like pathology (20). Previously, Ang and colleagues have 
found in a murine model that with ascorbate supplementation, TAM phenotype shifts to a form 
that is neither clearly pro- or anti-tumour (45). Moreover, TET2’s activity, which could be 
involved with both immunostimulatory and immunosuppressive functions, is enhanced by 
ascorbate supplementation (106, 108, 109, 120). This gives rise to the following questions: 1) 
Can ascorbate supplementation alter TAMs phenotype in humans, and 2) does TET2 have a 
role in these modified phenotypes. If an altered TAM phenotype can be generated in humans, 
the follow-up question is whether this modified phenotype could dampen the inflammatory 
cascade and limit the severity of irAEs, while at the same time maintain an immunostimulatory 
environment. If so, could ascorbate be used as an adjuvant in anti-PD1 immunotherapy to 
support immune cell function?   
 
In light of these questions and the current literature, this pilot study aimed to establish an in-
vitro model to study the effects of melanoma cell condition media on monocytes/Mϕ 
phenotype and function, and to answer the following questions: 1) Can ascorbate 
supplementation alter TAMs phenotype and give rise to heterogenic subpopulations in a human 
model. 2) Does ascorbate supplementation alter TET2 activity in these Mϕs.  
 
I hypothesised that with the addition of PBMCs into melanoma-derived conditioned media the 
Mϕs would be influenced by cancer cell-derived growth factors, chemokines, cytokines and 
other factors and pushed towards a pro-tumourigenic phenotype. However, upon 
supplementation with ascorbate, I hypothesised that this phenotype would be altered towards 
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a combined immunosuppressive and immunostimulatory phenotype. Moreover, with ascorbate 
supplementation, I hypothesised that TET2 activity would increase in these altered Mϕs.      
 
Therefore, the aims of this project were: 1) use RT-qPCR to measure expression of a panel of 
genes indicative of Mϕ function, 2) use immunohistochemistry to determine the presence and 
intensity of immunosignal for key phenotypic and lineage cell markers, and 3) use Mass 





















Chapter 2 – Materials and Methods:  
 
Prior to any experimental work, ethics for the harvesting and working with human material 
was obtained from UO Human Ethics Committee. The Hepatitis B vaccine was also received 
before the start of blood work.   
  
2.1.  Media  
Phosphate Buffered Saline (PBS): One 5g  PBS tablet (Gibco, Thermofisher, UK) was 
dissolved in 500mL of milliQ water (NW Ultrapure Water System, Superseries, Heal Forceâ). 
The solution was fully dissolved prior to being autoclaved. Sterile 1X PBS was stored at room 
temperature. Dulbecco’s Phosphate Buffered Saline (DPBS) (Gibcoâ, Life TechnologiesTM, 
UK) was used when available, as it is endotoxin free.    
 
Phosphate Buffered Saline (PBS) + 2% Foetal Bovine Serum (FBS): FBS (Hyclone, Global 
Life Science Solution, NZ) was heat inactivated by being placed into a 55℃ water bath for 20 
minutes. Subsequently, 10mL of heat-inactivated FBS was aseptically transferred to 490mL of 
sterile 1X PBS. The final solution was stored at 4℃.      
 
Serum-free media and cell culture media: To 470mL of Roswell Park Memorial Institute 
(RPMI) medium 1640 + GlutaMax media (Gibcoâ, Life TechnologiesTM, USA), 5mL of 
Penicillin-Streptomycin (P/S) (10000-units/mL Penicillin and 10000 g/mL Streptomycin) 
(Gibcoâ, Life TechnologiesTM, USA) and 25mL of heat-inactivated FBS was aseptically 
transferred, achieving a final concentration of 1% P/S and 5% FBS. The resultant cell culture 




Similarly, serum-free media was generated through the addition of 5mL of P/S to 495mL of 
RMPI 1640 + GlutaMax media, achieving a final concentration of 1% P/S. The media was 
stored at 4℃ until use.  
 
NZM9, NZM40 and NZM42 Conditioned media: NZM9, NZM40 and NZM42 are metastatic 
melanoma cell lines that were generated by Professor Bruce Baguely (University of Auckland) 
and kindly shared by Doctor Martina Paumann-Page (University of Otago, Christchurch). Cell 
lines were cultured in tissue culture dishes (Corningâ, Incorporated Life Sciences, China) 
under 5% oxygen conditions within a hypoxic chamber (Xvivo system x3, Biospherix), with 
cell culture media changes occurring every two days for maintenance. In generating 
conditioned media, cells were seeded at 8.8x104 cells/cm2 with a media volume to surface area 
ratio of 0.36 mL/cm2. After 48hrs of culture, the supernatant was removed and aseptically 
transferred to a 50mL falcon tube (Corningâ, Incorporated Life Sciences, China), before being 
centrifuged at 1,000g for 5mins. Subsequently, supernatant was aliquoted into sterile 1.7mL 
eppendorf tubes (AxyGenâ, Corningâ, China) and stored within an -80℃ freezer.  
 
Ascorbate solution: 10mg of (+)-Sodium L-Ascorbate powder (Sigma-Aldrich) was measured 
and transferred to a 1.7mL tube, prior to being dissolved in 1X PBS to achieve a 10mg/mL 
(50mM) stock solution. Following complete dissolution, the solution was aspirated with a 
disposable 1mL syringe (Interlab Ltd, NZ) and filter sterilised with a 0.22𝜇m syringe filter 
(ReliaPrepTM, Ahlstrom, Interlab Ltd, NZ). Using 1X PBS, the stock solution was diluted 1:5 
to create a 10mM working stock.  The resultant ascorbate solution was diluted appropriately 




1X Tris-acetate-EDTA (TAE): 20mL of 50X TAE stock was aseptically transferred to 980mL 
of milliQ water and mixed. 1X TAE was stored at RT.  
 
Immunocytochemistry blocking agent: 10mg of bovine serum albumin (BSA) (Gibcoâ, Life 
TechnologiesTM, NZ) and 22.52mg of glycine (AnalaRâ, BDH Laboratory Supplies, England) 
was added per mL of 1X PBS. The resultant solution was used immediately.     
 
Phosphate Buffered Saline with 0.1% Tween (PBST): 200𝜇L of tweenÒ20 (Sigma-Aldrich, 
Life TechnologiesTM, France) was transferred to 200mL of 1X PBS, achieving a final 
concentration of 0.1% (v/v). Subsequently, the solution was sterilized using 0.22𝜇m syringe 
filters and stored at 4℃.  
 
2.2.  Blood Harvest and Processing 
2.2.1.  Blood Collection from Donors 
With signed consent, 35-50mL of blood was harvested per volunteer by a trained phlebotomist 
at Nicholls Clinical Research Centre, using a 60mL syringe. Blood was transferred to a 50mL 
falcon tube containing 5000units/mL heparin (Fisher BioReagents, ThermoScientific) to 
prevent coagulation, allowing the immediate transportation of harvested material to a Class II 
biosafety cabinet. Blood was harvested from twelve volunteers, male and female identification 
and ranged 20-55 years of age, over the entirety of the study. Each volunteer donated once.   
 
2.2.2.  Isolation of Peripheral Blood-derived Monocytes 
Modifying the protocol from SepMateTM procedure, processing began with the transfer of 
15mL of Lymphoprep density gradient medium (STEMCELL Technologies, Canada), into the 
lower compartment of SepMateTM tubes (STEMCELL Technologies, Canada). After being 
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diluted to a 1:1 ratio with 1X PBS + 2% FBS, blood was transferred to the prepared SepMateTM 
tubes. Subsequently, tubes were centrifuged at 1200g for 10mins, with speed 7 for acceleration 
and deacceleration, allowing for the separation of peripheral blood mononuclear cells (PBMCs) 
from polymorphonuclear cells (PMNs) and red blood cells. PBMCs were transferred from the 
SepMateTM tubes and transferred into a 50mL falcon tube, before being further topped up with 
1X PBS + 2% FBS solution to a final volume of 50mL. The diluted serum was then centrifuged 
at 300g for 8mins, with speed 7 for acceleration and deacceleration. The resultant supernatant 
was aspirated and the pellets were resuspended, and pooled with 20mL of 1X PBS + 2% FBS 
solution. Into a 0.6mL eppendorf tube (AxyGenâ, Corningâ, China), dilutions were made with 
1X PBS to achieve an estimated concentration of 0.5 x 106 cells/mL for subsequent cell 
counting (protocol found under section 2.3). In addition, 1 x 106 cells were set aside for 
intracellular ascorbate measurement (protocol detailed under section 2.5), while the remaining 
solution was further diluted with 30mL of 1X PBS + 2% FBS and centrifuged at 300g for 
8mins, with speed 7 for  acceleration and deacceleration. The solution was then aspirated and 
the pelleted cells were resuspended in serum-free media, achieving a cell concentration of 4 x 
106 cells/mL. The resultant cellular suspension was aliquoted over 12-well and 48-well Nunc 
plates (NuclonTM Delta Surface, ThermoScientific), at 1mL and 250𝜇L per well, respectively, 
for downstream growth. To actively select for monocytes, plates were incubated at 37℃ for 
2hrs, before the present serum-free media was used to flush the wells and replaced with fresh 
media, taking advantage of the cell’s adhesive capabilities. A schematic of this monocyte 




















2.3.  Cell Counting   
Cell counting was performed with the aid of a hemocytometer (Marienfield Superior, 
Germany). 10𝜇L of sample was transferred to the hemocytometer and cells within the four 
outer squares of the grid were counted independently. The average cell count from the four 
squares was determined and multiplied by a factor of 104, to determine the cellular 
concentration (cells/mL). If any other dilutions were performed, these were taken into account 
when calculating the cell concentration.       
 
2.4.  Isolated Peripheral Monocyte Culture and Stimulation  
2.4.1 Peripheral Monocyte Culture 
Isolated cells were maintained at 5% O2 tension in either cell culture media supplemented with 
10 ng/mL MCSF or melanoma derived conditioned media (20% or 40% v/v) that was refreshed 
Figure 2.1: Schematic of Monocyte Isolation Protocol. Blood was separated into components 
and the serum was excluded. With several washes, white blood cells were isolated and 
resuspended in serum-free media. The resultant solution was aliquoted over 12- and 48-well 





on days two, four and six. Cells in 12 well and 24 well plates were fed with 1 mL and 0.5 mL 
of media respectively. In some instances, cells were stimulated with known inducers to 
generate an M1-like or M2-like phenotype on day six (refer to section 4.2). Cells were then 
harvested on day seven for downstream analysis. 
 
2.4.1.1.  Experimental conditions for ascorbate uptake 
Isolated peripheral monocytes were cultured with MCSF (10 ng/mL) for seven days. On day 
seven, cells were supplemented with 0𝜇M, 100𝜇M, 200𝜇M or 400𝜇M of ascorbate. After 
24hrs, wells were washed with 1mL of 1X PBS three times, prior to adding 200𝜇L of Accutase 
(Innovative Cell Technologies, Sigma-Aldrich, USA). After 35-45mins, the Accutase was 
flushed over the cells and the supernatant was transferred to a 1.7 mL eppendorf tube. Cell 
counting was then performed (protocol found under section 2.3) and cell concentrations were 
recorded. The remaining cells were estimated for volume using a micropipette to determine the 
absolute number of cells in suspension. Cells were then pelleted and processed for ascorbate 
measurement as described in section 2.5.  
 
2.4.2.  Experimental Conditions for Gene Expression, Cell Surface Marker and Epigenetic 
Analysis  
For this project, isolated peripheral monocytes were cultured under experimental conditions 
using cell cultured supplemented with: 1) 10𝜇g/mL macrophage colony stimulating factor 
(MCSF), 2) MCSF + 25ng/mL lipopolysaccharide (LPS) + 50𝜇g/mL interferon gamma (IFN-
𝛾), 3) MCSF + 20𝜇g/mL interleukin 4 (IL-4) + 20𝜇g/mL interleukin 13 (IL-13), 4) 20 and 40% 
(v/v) NZM9, NZM40 and NZM42-derived conditioned media, and 5) 20% (v/v) NZM9, 
NZM40 and NZM42-derived conditioned media + 100𝜇M ascorbate supplementation. 
Schematics of the different experimental conditions within 12-well Nunc plates, can be found 
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in table 2.1, 2.2, 2.3 and 2.4. It should be noted that in all downstream experimental sections, 
protocols utilized cells cultured in plates with the well layouts displayed in table 2.3 and 2.4. 
Furthermore, schematics of the conditions within 48-well Nunc plates, can be found in table 
2.5, 2.6 and 2.7.  
 
All cytokines (Peprotech, USA) used to create the different experimental conditions were 
reconstituted in 0.1% BSA PBS, to the working concentrations listed above and stored at -
80℃. Prior to immediate use, LPS required a further 1:10 dilution in cell culture media to 
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Table 2.1: Well Layout of the Initial Experimental Conditions on a 12-well Plate  
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2.5.  Ascorbate Measurement 
2.5.1.  Preparation of Samples for Ascorbate Measurement 
Cell suspension set aside after PBMC isolation, and cultured monocytes for ascorbate uptake 
were processed as follows to measure intracellular ascorbate content. To create a pellet, 
samples were centrifuged at 400g for 3mins. Subsequently, the supernatant was discarded and 
the pellets were resuspended in 100𝜇L of 0.54M perchloric acid (PCA) (OptimaTM, Fisher 
Chemical, ThermoScientific). Following 5mins of incubation on ice and vigorous vortexing, 
the samples were centrifuged at 15,000g for 5mins at 4℃, before the supernatant was 
transferred to a sterile 1.7mL eppendorf tube and stored in a -80℃ freezer. 
 
 
Table 2.3: Well Layout of the Confirmed Experimental Conditions for Downstream 
Experiments, on a 12-well Plate 
Table 2.4: Well Layout of Ascorbate Measurement Experimental Conditions on a 12-well Plate 
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2.5.2.  Ascorbate Measurement with High-Performance Liquid Chromatography (HPLC) 
Prior to HPLC, thawed samples from freshly isolated PBMCs and ascorbate uptake 
experiments were centrifuged at 15,000g for 5mins at 4℃, ensuring that there was no debris in 
the supernatant. Subsequently, 80𝜇L of supernatant was transferred into the plastic inserts of 
autosampler vials. Following transfer, ascorbate within the supernatant was measured and 
analyzed by the high-performance liquid chromatographer, Ultramate 3000 with 
electrochemical detection (ThermoScientific). A schematic of the isolation and preparation of 
ascorbate for HPLC can be found in figure 2.2. Dr. Juliet Pullar kindly performed the HPLC 
and created standard curves using known standards. Through these standard curves, the 






Figure 2.2: Schematic of Ascorbate Supernatant Preparation for HPLC. In summary, cells that were 
recently isolated from blood or monocytes/macrophages were cultured for seven days. Supernatants 
containing ascorbate were placed in plastic inserts of autosampler vials and subjected to HPLC for 
the measurement of ascorbate concentration. Figure was created on BioRender.com   
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2.6.  Immunocytochemistry  
Antibody concentrations were initially optimized using a protocol similar to that detailed in the 
following paragraphs. Relevant information regarding antibodies used, suppliers and stock 
concentrations can be found in table 2.8 and 2.9.          
 
2.6.1.  Fixing and Blocking Cells 
After 24hrs of stimulation from day six, 48-well plates were removed from the hypoxia 
chamber and the media was removed. To fix the cells, 250𝜇L of ice-cold methanol (Merck, 
Sigma-Aldrich) was transferred into wells for 5mins at RT. Subsequently, the wells were 
washed with ice cold 1X PBS three times, before 250𝜇L of blocking agent was transferred into 
the wells and incubated for 45mins at RT. Following this, the wells were once more washed 
with 1X PBS and then left to air dry overnight prior to being wrapped in tin foil, to minimize 
condensation, and stored at -80℃.         
 
2.6.2.  Application of Primary and Secondary Antibodies – Characterisation of Macrophage 
Phenotype 
Primary antibodies against CD68, CD206 and HLD-DR were diluted by with 1% BSA by 
1:100, 1:1000 and 1:50, respectively. Mouse (Ms), Rabbit (Rb) and Rat (Rt) IgG antibody 
controls were initially diluted to the same concentration as the antibody with the highest 
concentration that they were controlling for. In other words, Ms was diluted 1:25, Rb was 
diluted 1:15 and Rt was diluted 1:2.5 in 1% BSA solutions, before the IgG controls were further 
diluted by the same factor as their highest concentrated counterparts. The resultant surface 
marker 1% BSA solution was aliquoted over the wells at 100𝜇L per well, while the IgG 
solution was aliquoted over control wells at the same volume. Subsequently, water was pipetted 
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into the surrounding wells, to create a humid environment that would minimize the evaporation 
of antibody solutions, and the primary antibody solutions were left in the wells for 2hrs at RT.  
 
Following the 2hrs incubation, wells were washed three times with 250𝜇L of 0.1% PBST, and 
plates were placed on Orbital shakers (Edwards Instrument Co, Bioline) for 10mins between 
washes. In 1% BSA, secondary antibodies Rb 647, Rt 488 and Ms 594 were diluted by a factor 
of 1:500, before the solution was aliquoted into wells at 100𝜇L for 1hr at RT in the dark. 
Subsequently, the wells were washed a further three times with 0.1% PBST. 4’,6-diamidino-
2-phenylindole (DAPI) was then diluted by a factor of 1:1000 in 1X PBS and aliquoted to the 
wells at 100𝜇L, for a total incubation period of 30 sec. Wells were then washed twice with 
0.1% PBST, before being rinsed twice with PBS. Finally, the wells were reconstituted with 
400𝜇L of 1X PBS.  
 
2.6.3. Application of Primary and Secondary Antibodies – Identification 
Monocyte/Macrophage Markers 
Similarly, staining against CD68 and CD14 followed the previous protocol, however, the Ms 
IgG control was diluted against CD14, as it was the more highly concentrated antibody. 
Furthermore, only the Ms 594 secondary antibody was required, as both CD68 and CD14 
belong to the same species. Staining against CD68 and CD14 was also performed on plates 
that were fixed/blocked on day zero and day seven, while staining against CD68, CD206 and 
HLA-DR only occurred on day seven plates. A schematic outlining the plates and associated 
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2.6.4.  Imaging and Processing for Immunocytochemistry  
Following reconstitution with 1X PBS, imaging was performed by ImageXpressâ PICO 
(Molecular Devices, Bio-strategy Ltd), which utilizes the software MD Cell ReporterXpress. 
Table 2.5: Well Layout of the Different Experimental Conditions and Associated Antibody Staining on a 48-
well Plate, After Seven Days of Culturing, For the Characterisation of Macrophage Phenotypes 
Table 2.6: Well Layout of the Different Experimental Conditions and Associated Antibody Staining on a 
48-well Plate, After Zero Days of Culturing, For the Identification of Monocyte/Macrophage Markers 
Table 2.7: Well Layout of the Different Experimental Conditions and Associated Antibody Staining on a 
48-well Plate, After Seven Days of Culturing, For the Identification of Monocyte/Macrophage Markers 
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This mode of imaging was performed, as adhered Mϕs are difficult to detach after culture and 
would have reduced the yield of cells analyzed. Examples of staining can be observed in figure 
2.3, prior to imaging on PICO. Moreover, a schematic of the staining, imaging and processing 
of cells can be found in figure 2.4.  
 
To measure the fluorescent intensities of the stained cells, images were analyzed by the open 
sourced software Cell Profiler (Broad Institute of MIT and Harvard, USA), as the required 
PICO analysis module was unavailable. Due to PICO’s output comprising of black and white 
images of separate fluorescent (colour) channels, images were initially overlaid and assigned 
a pseudocolour using ImageJ (National Institutes of Health, USA). The resultant tiff images 
were processed using a developed pipeline, adapted from those available on Cell Profiler’s 
website (122). In brief, the pipeline split the tiff images into individual channels, blue, green 
and red, (figure 2.5 A) and in sequence: 1) Traced and measured the intensity of blue staining 
(nuclei) (figure 2.5 B)  in the blue channel. 2) Using the nuclei as a reference point to a cell, 
traced and measured the fluorescence intensity of red (CD206) (figure 2.5 D) and green 
(HLADR) (figure 2.5 E), in the red and green channels, respectively. Staining that could not 
be associated with a cell was discarded. 3) Generated excel sheets with the staining intensity 
output values. A limitation of the pipeline was that it restricted analysis to three channels at 
any time. Therefore, while cells were stained for CD68, CD206, HLADR and nuclei, two 
groups entered the pipeline: 1) Nuclei, CD206 and HLADR, and 2) Nuclei and CD68. The two 
groups were processed by the same pipeline detailed above, but CD68 was measured instead 
of CD206 (figure 2.5 C) and measurement in the green channel was excluded from the 
pipeline. This was possible as the PICO’s output comprised of separate channels, enabling 
different overlaid combinations to be generated on ImageJ. The resultant excel sheets were 
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combined after processing, allowing correlation of all CD68, CD206, HLADR and nuclei 






Figure 2.3: Staining of Cellular Markers on Monocyte/Macrophage Populations. Immunocytochemistry was 
performed on cellular populations immediately or following seven days of culturing, and were imaged using PICO 
in conjunction with MD Cell ReporterXpress. Blue staining in A, B, C and D represents the nucleus. Pink staining 
in B indicates CD206. Red and green staining in C indicates CD68 and HLA-DR, respectively. While the red 




















Figure 2.4: Schematic of Staining, Imaging and Processing of Monocytes/Macrophages. In brief, cells 
were stained with primary and secondary fluorescent antibodies, before being imaged by PICO. The 
resultant images were subsequentially processed by a pipeline developed and run in Cell Profiler. 
















Figure 2.5:  Schematic of Image Processing by the Developed Pipeline. Imaged channels were overlaid and 
assigned a pseudocolour on ImageJ. The resultant images were subjected to the pipeline developed and ran 
in Cell Profiler. Limitations of the pipeline separated the processing of stained markers into two groups: 1) 
Nuclei, CD206 and HLADR. 2) Nuclei and CD68. Both runs share the initial steps of the pipeline A and B, 
indicated by the black arrow. A) Image was separated into green, blue and red channels. B) Nuclei was traced 
and blue intensity was measured in the blue channel. Following nuclei measurement, the pipeline diverges, 
identifiable by the orange and green arrows. C) CD68 was traced and related to nuclei. Red intensity was 
then measured in the red channel. D and E) CD206 and HLADR, respectively, were traced and related to 
nuclei. Red and green intensity of CD206 and HLADR objects, respectively, was measured in the red and 






Using Cell Profiler output excel sheets, cells were sorted into subpopulations. To remove non-
specific fluorescence and sort for true surface markers, the mean intensity of red and green 
staining found in IgG controls was used as a threshold. Any intensity value below this threshold 
from the experimental conditions was removed. Moreover, to remove fluorescence saturation, 
frequency distribution histograms were created (figure 2.1.1, appendix 2) and with visual 
confirmation from plots generated by Cell Profiler, saturation was identified and a maximum 
intensity threshold of 300 was set. Any value above this threshold was removed. With the 
removal of non-specific fluorescence and saturation, cells were sorted into subpopulations, 
depending on the combination of cell surface markers (CD68, CD206 and HLADR) present. 
These populations were further filtered into low, intermediate and high marker expression 
subpopulations. This was based on the 25 and 75 percentile values observed in populations 
derived from media + MCSF wells: Low, less than 25 percentile; Intermediate, between 25-75 
percentile; High, more than 75 percentile.  Frequency of these subpopulations as a percentage 
of the whole population that they derived from was then calculated.      
 
Table 2.8: Primary Antibodies and their Associated Cellular Targets 
Antibodies Supplied Concentration 
CD14 Ms Ab181470 Ms 1mg/mL 
CD68 Ms DAKO M0876 Ms 0.04mg/mL 
CD206 Rb Abcam Ab64693 Rb 1mg/mL 
HLA-DR Rt Novus NB100-64935 1mg/mL 
Nucleus – DAPI (blue) Invitrogen D1306 10mg/mL 
Ms IgG (control) Invitrogen 31903 5.05mg/mL 
Rb IgG (control) DAKO X0936 15mg/mL 





Antibody Supplied Concentration Secondary to: 
Ms 594 (Alexa fluor 568/Texas Red) Abcam ab150116 2mg/mL CD14 and CD68 (Ms) 
Rb 647 (Alexa fluor 647/Cy5 - Pink) Abcam ab150063 2mg/mL CD206 (Rb) 
Rt 488 (FITC - Green) Abcam ab150153 2mg/mL HLA-DR (Rt) 
 




2.7.  DNA/RNA Extraction from Cultured Cells             
After 24hrs of stimulation from day six, 12-well plates were washed twice with 1X PBS, prior 
to being subjected the DNA/RNA extraction protocol, as per manufacturer’s instructions 
(Quick-DNA/RNATM Miniprep Plus Kit, ZYMO Research, USA). The optional DNase I step 
within the protocol was performed for all experiments. Adaptions to the manufacturer’s 
protocol included increasing the DNA/RNA lysis buffer to 400𝜇L per well and then scraping 
the wells with the pipette tip to detach cells, repeating the elution step twice, preheating milliQ 
water in a 37℃ incubator for eluting and decreasing the elution volume to 50𝜇L for RNA. The 
resultant elution’s were measured using a Nanodrop 8000 V2.2 Spectrophotometer 
(ThermoScientific), using the corresponding software. Samples were stored in the -80℃ freezer 
until required. 
 
If the samples had to be concentrated, the samples were pooled and after refreezing the samples, 
they were placed within a speed-vacuum centrifuge with the eppendorf tube caps open and 
temperature set to low. This speed-vacuum centrifuge comprised of several machines, 
including the refrigerated vapor traps RVT405DDA and RVT4104 (Savant, ThermoScientific), 
the vacuum pump oil filter VPOF110 (Fisherscientific, ThermoScientific), and the oil mist 
filter EMF 10 (Savant, ThermoScientific). After 20mins, RNA samples were removed from 
the machine, while DNA samples were centrifuged for 2hrs. Subsequently, RNA samples were 
resuspended with 14𝜇L of milliQ water, while DNA samples were resuspended with 20𝜇L. 
New concentrations were measured using the Nanodrop and the samples were stored at -80℃ 






2.8.  Mass Spectrometry  
Using a Nucleoside Digestion kit (Biolabsâinc, New England), nucleotides were liberated for 
downstream analysis by mass spectrometry, as per the manufacturer’s instructions. If 
necessary, HPLC-grade water (Fisher chemical, USA) was added to the mix, to achieve a final 
volume of 20𝜇L, and the sample was spiked with with 85 fmoles of cytidine, 5 fmoles of (5mC) 
and 0.13 fmoles of (5hmC) heavy isotopes, supplied by Dr. Nick Magon. Following the 
necessary incubation, 5𝜇L of HPLC-grade water was transferred to the samples, prior to the 
solution being transferred into the plastic insert of autosampler vials. A schematic of the setup 
for mass spectrometry can be found in figure 2.6. Subsequently, Dr. Nick Magon was provided 
with the samples and he kindly performed the liquid chromatography coupled mass 
spectrometry, on QTRAPâ6500 (AB Sciex). Dr Magon used a  previously established 
laboratory protocol for the measurement of cytidine, methylcytidine and 
hydroxymethylcytidine  and generated standard curves for the markers of interest, using known 
standards (123). It should be noted that cytidine is cytosine when attached to a ribose sugar 
(124). Through these standard curves, the unknown concentrations of the supplied samples 
were determined, and subsequentially converted to percentages of total cytidine.        
 
 
Figure 2.6: Schematic of DNA Preparation for Mass Spectrometry. In summary, DNA was 
isolated from monocytes/macrophages and nucleotides were liberated, and labelled with heavy 
isotopes. The resultant solution was placed in the plastic insert of autosampler vials and 




2.9.  Agarose Gel Electrophoresis 
2.9.1.  Testing Gene Primers and Quality of Real-time Quantitative Polymerase Chain 
Reaction (RT-qPCR) Products  
To test the suitability of gene primers and specificity of real-time quantitative polymerase chain 
reaction (RT-qPCR) products, gel electrophoresis was performed. Using SeaKemâ LE Agarose 
powder (Lonza Bioscience, Rockland, USA) and 1X TAE buffer, gel solution was created at 
1.5% agarose concentration. Subsequently, SYBRâ safe DNA gel stain (Invitrogen, USA) was 
transferred to the solution, achieving a 1:10,000 dilution from the provided stock solution 
(10,000X in DMSO). The resultant solution was poured into gel holders and left to harden. 
Placed correctly in a gel tank, 1X TAE was poured into the tank to submerge the gel by a 
minimum of 0.5cm. 10𝜇L of sample was then mixed with 1𝜇L of 6x Tn Track DNA loading 
buffer (ThermoScientific, Lithuania) and loaded into the gel’s wells. 4𝜇L of GeneRuler 100bp 
DNA ladder (Molecular Biology, ThermoScientific, Lithuania) was transferred to the first and 
last wells of the gel and the gel was left to run for 40mins at 100 volts on PowerPac BasicTM 
(BioRad). Following a run, gels were imaged using a gel documentation system (Q9 Advanced 
Alliance, UVITEC Cambridge), with the associated Nine Alliance program.  
 
2.9.2.  Testing RNA Quality 
To test the quality of RNA, the above protocol was followed, but with the addition of 1% Janola 
Premium bleach (Pental, Australia) to the gel solution. In accordance with the protocol 
described by Aranda and colleagues in ‘Bleach gel: A simple agarose gel for analyzing RNA 






2.10.  Complementary DNA (cDNA) Reverse Transcription  
Using the extracted RNA, cDNA synthesis was performed using the protocol and reagents 
provided by High Capacity cDNA Reverse Transcription kits (Applied Biosystems, 
ThermoScientific). The kit without the RNase inhibitor was utilized. However, adjustments 
were made to the protocol to include anchored oligo dT (20) primers (ReadyMadeTM Primers, 
Integrated DNA Technologies), equivalent to 1𝜇L per reaction, and reducing the volume of 
milliQ water by the same amount. Subsequent to the creation and distribution of the mastermix, 
10𝜇L or the equivalent of 0.2 – 0.5𝜇g of RNA, depending on the achievable concentration 
based on the initial RNA concentrations was added. If required, additional milliQ water was 
transferred to mix, ensuring that 20𝜇L was present per reaction. cDNA synthesis was then 
performed on the 2720 Thermal Cycler (Applied Biosystems, ThermoScientific), following the 
protocol outlined by the kit’s manual.       
 
2.11. Real-time Quantitative Polymerase Chain Reaction (RT-qPCR)    
2.11.1.   Setting Up and Running RT-qPCR    
Using the reagents from a BIOTAQTM DNA polymerase kit (Meridian BioscienceTM, Bioline), 
and if needed - dNTP mix (Meridian BioscienceTM, Bioline), a mastermix was created for RT-
qPCR. While the manual was used as a guide, the reagent volumes per reaction were adapted 
and optimized by Dr. Abel Ang. In addition, EvaGreenâ (20X in water, Biotium) was added to 
the mastermix, reducing the required milliQ water volume. This allowed for the measurement 
of double stranded DNA by fluorescence, enabling analysis of real-time PCR progression and 
quantification of gene expression. The volumes used are listed within table 2.10. Furthermore, 
primers (commercially sourced from either Origene or NIH primer Blast and ordered through 
Life Technologies, ThermoScientific, Japan, by Dr. Abel Ang) were reconstituted and diluted 
to 2𝜇M working stock, while cDNA was diluted with milliQ water by a factor of 1:3, to be 
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used as templates. RT-qPCR primers were tested and a detailed list of primers that were 
unsuccessful and those that replaced the unsuccessful primers or were successful, can be found 
in table 4.3.1 and 4.3.2, respectively, Appendix 4.3. The final gene panel can be found in 
table 2.11. The expression of each gene under different experimental conditions, including a 
no template control (NTC), was analyzed. To substitute for a template, milliQ water was used 
within NTC conditions. The resultant solutions comprised of cDNA for a particular 
experimental condition and a forward, and reverse primer of a gene. These solutions were 
aliquoted in triplicates at 9.8𝜇L per well into a Framestarâ 384-well skirted plate, Roche style 
(4titude, UK). A schematic of the well layout for aliquoted solutions can be observed in figure 
2.8. Once the solutions were aliquoted, the plate was encased with plateSealerTM (Ultident, 
USA) and was spun down by the mini-P25 centrifuge (Interlab, NZ). RT-qPCR was then 
performed on the plate, using a LightCyclerâ 480 II PCR machine (Roche Life Science), which 
utilizes the associated LightCyclerâ 480 SW 1.5.1 software. A schematic of the RT-qPCR 
setup can be found in figure 2.7.    
 
It should also be noted that to setup and perform the RT-qPCR within a reasonable timeframe, 
gene expression for each of the target genes was performed over two runs of the protocol, using 
the same 384-well plate. Thus, analysis of housekeeping genes expression was performed 








2.11.2.  Analysis of RT-qPCR Results 
Subsequent to the completion of the RT-qPCR run, LightCyclerâ 480 SW 1.5.1 software was 
used for downstream analysis of melting curves, which in conjunction with gel electrophoresis 
of PCR products, allowed for quality control of the data (detailed in appendix 4.4). 
Furthermore, the software allowed for the calculation of cycle threshold (CT) values, which 
then allowed for the relative gene expression to be calculated as a fold-change in difference to 
the expression observed under media + MCSF (positive control), and then normalized against 
Figure 2.7: Schematic of RT-qPCR setup. In brief, RNA was harvested from cells and utilised for 
the synthesis of cDNA. Subsequently cDNA was amplified with primers and in the presence of 
EvaGreen. The resultant output was used for the calculation of relative gene expression. Figure was 
created on BioRender.com 
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the housekeeping genes HPRT1 expression. The equation used for this calculation of relative 
expression was derived from Pfaffl and colleagues method, comprising of the following (126);  
= 2^ - ((gene expression under condition A - HPRT1 expression under condition A) - (gene 
expression under media + MCSF - HPRT1 expression under media + MCSF))                    
 
 
PCR Reagent Volume per reaction (𝝁L) 
Buffer 1 
MgCl (50mM) 0.5 
dNTP (5mM) 0.4 
TAQ Pol. 0.075 
Forward primer (2𝜇M) 1 
Reverse primer (2𝜇M) 1 
Template 1 
Eva Green 0.5 







Forward Primer Reverse Primer 
MRC1 134 TCAGATATGCCAGGGCGAAA GGGTGGGTTACTCCTTCTGC 
TFG-𝛽1 173 CAAGTGGACATCAACGGGTTC TCCGTGGAGCTGAAGCAATAG 
IL10 175 GGCACCCAGTCTGAGAACAG GGCAACCCAGGTAACCCTTA 
IL-1𝛽 116 AGCCATGGCAGAAGTACCTG CCTGGAAGGAGCACTTCATCT 
TNF-𝛼 189 TCTCCTTCCTGATCGTGGCA CAGCTTGAGGGTTTGCTACAAC 
MMP-2 138 AGCGAGTGGATGCCGCCTTTAA CATTCCAGGCATCTGCGATGAG 
MMP-9 177 CGCAGACATCGTCATCCAGT AACCGAGTTGGAACCACGAC 
VEGFA N/A TTGCCTTGCTGCTCTACCTCCA GATGGCAGTAGCTGCGCTGATA 
TET2 100 AGCAAGATGGCTGCCCTTTA AATGTTTGCCAGCCTCGTTC 
B-actin 184 GCCGCCAGCTCACCAT TCGTCGCCCACATAGGAATC 





Table 2.10: Reagent Volumes Required for the Generation of a Mastermix for One Reaction 
N/A; The primers were designed bind/amplify all 7 variants of the gene products.  
Abbreviation: Bp; Base pair. 
Table 2.11: Final Gene Panel and Associated Primer Sequences Used for the Analysis of Gene Expression 








2.12.  Statistics  
Biological repeats were performed for all experiments to a minimum N=3, unless the level 3/4 
COVID-19 lockdown imposed by the New Zealand (NZ) Government prevented this. Data 
was checked for normality using the Shapiro-Wilk test and if datasets failed the test, frequency 
distribution histograms were used to confirm abnormal distribution (figure 3.1.1 in appendix 
3.1). Possible outliers were identified with ROUT (Q=1%). When appropriate, datasets that 
failed to pass the normality tests were transformed to their log10 forms, reducing any abnormal 
distribution that can arise from biological repeats. However, if inappropriate, nonparametric 
tests including the Friedman test followed by the Dunn’s multicomparison test were used for 
multifactorial comparisons, while two-tailed Wilcoxon matched-pairs signed rank test was 
used for pairwise comparisons.  
 
When data passed tests for normality, parametric tests including repeated measure (RM) one-
way ANOVA with Geisser-Greenhouse correction, followed by Tukey’s multicomparison test, 
with individual variances computed, was utilized for multifactorial comparisons. However, if 
the groups were unpaired, Ordinary one-way ANOVA, followed by Tukey’s multicomparison 
Figure 2.8: Schematic of the 384-well Plate Layout Used for the Analysis of Gene Expression Under Different 
Conditions. Solutions comprising of PCR reagents, including the necessary primers and cDNA for particular 
genes and conditions to be analyzed, respectively, were aliquoted in triplicates at 9.8𝜇L per well into a 384-
well plate.   














NTCMCSF MCSF + LPS + IFN-γ MCSF + IL-4 + IL-13 20% (v/v) NZM40 Condition media 20% (v/v) NZM40 Condition media + Ascorbate
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test was used. Moreover, one- or two-tailed paired or unpaired T tests were used for pairwise 
comparisons.   
 
All statistical analysis and graph creation was performed on GraphPad Prism 9.2.0 (GraphPad 























Chapter 3 – Results:  
3.1.  Selection of Experimental Conditions for Cell Growth 
Peripheral blood mononuclear cells (PBMCs) were harvested and isolated peripheral 
monocytes from PBMCs were cultured for seven days with different experimental conditions 
(section 2.2-4). Using the software CellSens Entry, wells were photographed at 10X objective 
on the microscope. As expected, MCSF supported the attachment of isolated peripheral 
monocytes and Mϕ proliferation (Figure 3.1 B), while cell culture media alone did not support 
this (figure 3.1 A). Isolated monocytes were also cultured in the presence of conditioned media 
prepared from primary human melanoma cell lines, NZM9, NZM40 and NZM42 at 20% and 
40% v/v. Among these conditioned medias, only NZM40 was found to support monocyte 
adherence and growth. As such, we discontinued the use of conditioned media from NZM9 
and NZM42 and used NZM40 at 20 % v/v. This concentration was chosen as it was able to 
















   
   








Figure 3.1: Growth of Peripheral Blood-Derived Monocytes under Different Medias. Wells were 
photographed using CellSens Entry software, with 10X objective on the microscope. Photomicrographs show 
cells grown at day seven in A) cell culture media. B) MCSF media. C) MCSF + LPS + IFN-𝛾 media. D) 
MCSF + IL-4 + IL-13 media. E) 20% (v/v) NZM40 conditioned media. F) 40% (v/v) NZM40 conditioned 
media. G) 20% (v/v) NZM40 conditioned media + ascorbate. H) 20% (v/v) NZM42 conditioned media. I) 
40% (v/v) NZM42 conditioned media. J) 20% (v/v) NZM42 conditioned media + ascorbate. K) 20% (v/v) 
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3.2.  Ascorbate Measurement and Determination of Ascorbate Supplementation Concentration 
3.2. 1.  Donor Intracellular Ascorbate Concentrations and Ascorbate Uptake Levels 
Intracellular ascorbate concentration was measured from PBMCs immediately after harvest as 
an indicator of immune cell ascorbate status. We were unable to measure the ascorbate status 
of freshly isolated peripheral monocytes specifically as monocytes make up a very small 
percentage of PBMCs (15%) and it would not be possible to isolate adequate amounts of 
peripheral monocytes to derive an accurate intracellular ascorbate measurement (127). 
Ascorbate content from monocytes/Mϕs that were cultured for seven days with MCSF (20 
ng/mL)  was also measured, as well as ascorbate uptake following 24hr exposure with either 
100, 200 or 400𝜇M of ascorbate on day seven of culture with MCSF. Cells were processed and 
ascorbate concentrations were measured by HPLC, utilising the standard curve and associated 
equation represented in figure 1.1.1, Appendix 1.1 (Section 2.4-5).   
 
Intracellular ascorbate concentrations of freshly isolated PBMCs were between 0.31 – 1.147 
nMoles per million cells within the healthy volunteers and differed between individuals (figure 
3.2). Following isolation and seven days of culture, intracellular ascorbate levels within 
monocytes/Mϕs supplemented with 0𝜇M of ascorbate were below the detection threshold of 
HPLC. However, with 24hr supplementation of 100𝜇M, 200𝜇M and 400𝜇M ascorbate, 
intracellular ascorbate concentration increased substantially surpassing the levels depicted in 
figure 3.2. While intracellular concentrations continue to increase as ascorbate concentrations 
increased, the degree of increase plateaued above 100𝜇M (figure 3.3). Statistically significant 
differences were observed when comparing 0𝜇M versus 100𝜇M (p=0.0096), 200𝜇M 
(p=0.0007) or 400𝜇M (p=0.0037) ascorbate concentration (Using the Shapiro-Wilks 
normality test; RM one-way ANOVA test followed by Tukey’s multicomparision test). This 





























Figure 3.2: HPLC-Analyzed Intracellular Ascorbate Concentrations of PBMCs Upon 
Blood Harvest. For every healthy volunteer, intracellular ascorbate concentration is 
measured and shown in nMoles per million cells.  
 
Figure 3.3: HPLC-Analyzed Macrophage Ascorbate Uptake Twenty-Four Hours After Exposure to Increasing 
Ascorbate Concentrations. Isolated peripheral monocytes were grown in MCSF (10 ng/mL) for 7 days prior 
to supplementation with ascorbate at 0, 100, 200 and 400𝜇M. Intracellular ascorbate was measured and is 
presented in nMoles per million cells. Data was obtained from N=7 healthy volunteers, with the mean and 
SEM shown for each dosage. RM one-way ANOVA with Geisser-Greenhouse Correction, followed by 
Tukey’s multicomparision test was performed across all dosages. Statistical significance is denoted * p≤0.05, 


















































































3.3. Monocyte to Macrophage Transition 
Monocytes/Mϕs immediately isolated from fresh blood (after 2hr incubation at RT to 
encourage monocyte adherence), and monocyte/Mϕs after day seven cultures were 
fluorescently stained and imaged on the same run. Acquired images were processed by a 
developed pipeline (section 2.6.4), and the output data was sorted into CD14+ and CD68+ 
subpopulations, which were converted into percentages of the whole population. 
CD14+:CD68+ ratios were calculated at day zero and day seven (figure 3.4) and derived from 
the subtraction of day zero values from day seven values (figure 3.5). Prior to sorting, IgG 
controls were used to remove non-specific fluorescence and fluorescence saturation was 
removed using frequency distribution histograms (examples highlighted in figure 2.1.1 and 
2.2.1, Appendix 2.1 and 2.2, respectively).  
 
With basal growth media (MCSF+) and stimulation (MCSF + LPS + IFN-𝛾, M1-like 
inflammatory; MCSF + IL-4 + IL-13, M2-like immunosuppressive) a pattern of CD14+:CD68+ 
ratios shifting favourably towards CD68+ subpopulations between day zero and seven was 
observed, reflecting a decrease in CD14+ monocyte and increase in CD68+ Mϕ subpopulations. 
However, when cells were cultured in 20% (v/v) NZM40 conditioned media, with or without  
100𝜇M ascorbate supplementation, their CD14+:CD68+ ratios reflected a minimal shift towards 
CD14+ monocyte subpopulations (figure 3.4). Figure 3.5 further shows these shifts towards, 
or away, from CD68+ subpopulations. Moreover, the figure highlights the increased movement 
towards CD68+ dominant populations in the positive controls, compared to MCSF media, while 












































































Figure 3.4: Transition of Monocyte to Macrophage Populations Over Seven Days Under Different 
Experimental Conditions. CD14+:CD68+ ratios were calculated and graphed for D0 and D7. CD14 
monocyte marker, CD68 macrophage marker. Data was obtained using cells monocytes/macrophages 





































































































Figure 3.5: Shift Towards CD68+ Subpopulations Between Day Zero and Day Seven of Culturing 
Over Experimental Conditions. CD14+:CD68+ ratios from day 0 were subtracted from those of day 
seven to produce the graphable values. CD14 monocyte marker, CD68 macrophage marker. Data was 
obtained using cells monocytes/macrophages from n=1 healthy volunteer. 
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3.4.  Cellular Functional Phenotypes 
3.4.1.  Cellular Functional Phenotype Frequencies 
 
Cells were stained, imaged and analysed using a developed pipeline. Subsequently, the output 
data was sorted into subpopulations based on the presence of CD68 (a marker of differentiated 
Mϕs), CD206 (a marker of M2-like or alternatively activated Mϕs) and HLADR (a marker of 
M1-like Mϕs) on the cell’s surface (section 2.6). Using the Shapiro-Wilk test, CD68+CD206-
HLADR+ and CD68+CD206+HLADR+ subpopulations failed normal distribution, confirmed 
using frequency distribution histograms, while the remaining subpopulations passed normality 
tests. This and downstream normality tests were confirmed using frequency distribution 
histograms (e.g., figure 3.1.1, Appendix 3.1).   
 
Statistical tests (Friedman test followed by Dunn’s multicomparison test or RM one-way 
ANOVA test followed by Tukey’s multicomparison test) determined that the differences in 
subpopulations across experimental conditions were not statistically significant (figure 3.6). 
However, differences in the frequencies of subpopulations can be observed, with 
CD68+CD206-HLADR- subpopulations decreasing in 20% (v/v) NZM40 conditioned media 
with or without 100𝜇M ascorbate supplementation, while CD68+CD206-HLADR+ frequency 
increased in MCSF + LPS + IFN-𝛾 media. CD68+CD206+HLADR- and 
CD68+CD206+HLADR+ subpopulations can also be observed to increase in 20% (v/v) NZM40 
conditioned media, with or without 100𝜇M ascorbate supplementation, respectively. 
Approximately 90% of the population were also identified to be of Mϕ lineage, across all 
experimental conditions. All SEM bars, with the exception of bars relating to 
CD68+CD206+HLADR- under MCSF, MCSF + IL-4 + IL-13 and 20% (v/v) NZM40 






























































































Figure 3.6: Presence of Different Macrophage Subpopulations Under Different Experimental Conditions. 
Immunocytochemistry data from Macrophages cultured from different experimental conditions was sorted into 
several subpopulations, based on the combination of CD68, CD206 and HLADR markers. Sorted 
subpopulations are represented as a percentage of the total population, shown by a stacked bar. The mean of 
subpopulations is graphed and can be identified by colour, and SEM bars are included. Data was obtained from 
N=3 healthy volunteers. Friedman test followed by Dunn’s multicomparison test was performed on 
CD68+CD206-HLADR+ and CD68+CD206+HLADR+ subpopulations across different experimental conditions. 
While the remaining populations were subjected to RM one-way ANOVA  with Geisser-Greenhouse correction, 
followed by Tukey’s multicomparison test. No statistical significance was detected.        
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From the CD68+CD206+HLADR- and CD68+CD206-HLADR+ populations detailed in figure 3.6, 
cells were further sorted into low, intermediate or high marker expression subpopulations. This 
was based on the 25 and 75 percentile values observed in populations derived from media + 
MCSF wells – Low: less than 25 percentile. Intermediate: between 25-75 percentile. High: 
more than 75 percentile. Using the Shapiro-Wilk normality test, both CD206inter/highHLADR- and 
CD206-HLADRinter/high subpopulations passed normal distribution, while CD206lowHLADR- and 
CD206-HLADRlow failed.  
 
No statistical significance in differing subpopulation frequency over the experimental conditions 
was detected (using the RM one-way ANOVA test followed by Tukey’s multicomparison test or 
Friedman test followed by Dunn’s multicomparison test). Nevertheless, within figure 3.7 A, the 
frequency of CD206high subpopulations showed an observable increase in 20% (v/v) NZM40 
conditioned medias, with or without 100𝜇M ascorbate supplementation, which is associated with 
a decrease in CD206inter subpopulations. Moreover, under 20% (v/v) NZM40 conditioned media, 
CD206low frequency also showed an observable decrease. All SEM bars, particular those associated 
with mean values obtained using MCSF + LPS + IFN-𝛾 media, showed high variability around the 
mean. This was with the exception of SEM bars in cells cultured with MCSF media, as this dataset 
was used to determine the sorting percentiles.             
 
Within figure 3.7 B, HLADRlow and HLADRinter subpopulations show an observable decrease with 
MCSF + LPS + IFN-𝛾 and 20% (v/v) NZM40 conditioned media with ascorbate, respectively. 
Moreover, the population stack under MCSF + LPS + IFN-𝛾 media does not achieve 100%, due to 
one donor not producing CD206-HLADR+ subpopulations. This is also observable with 20% (v/v) 
NZM40 conditioned media, which shows the lack of bar, as no donors produced the CD206-
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HLADR+ subpopulation. Similar to figure 3.7 A, SEM error bars are large except for SEM error 























Figure 3.7: Presence of Subpopulations as a Total Percentage of CD68+CD206+HLADR- or CD68+CD206-
HLADR+ Macrophage Populations. Derived from CD68+CD206+HLADR- and CD68+CD206-HLADR+ 
subpopulations, sorted from Macrophages cultured under different experimental conditions, these subpopulations 
can further be sorted depending on the intensity of markers present on cells. A: Populations were sorted into 
subpopulations, based on the presence of CD68, a lack of HLADR and whether CD206 was present at high, 
intermediate (inter) or low frequencies on cells. B: Populations were sorted into subpopulations, based on the 
presence of CD68, a lack of CD206 and whether HLADR was present at high, intermediate or low frequencies. 
Data was obtained from N=3 healthy volunteers. The means of subpopulations over different experimental 
conditions are graphed as stacked bars, representing percentages of the total population. Different subpopulations 
can be identified by colour and SEM error bars are shown. RM one-way ANOVA test with Geisser-Greenhouse 
correction followed by Tukey’s multicomparison test was performed on CD68+CD06interHLADR-, CD68+CD206-
HLADRinter and CD68+CD206-HLADRhigh subpopulations across different experimental conditions. While 
Friedman test followed by Dunn’s multicomparison test was performed on CD68+CD206lowHLADR-, 







































































































































































From the CD68+CD206+HLADR+ populations shown in figure 3.6, cells were further sorted into 
low, intermediate or high marker expression subpopulations. Using the Shapiro-Wilk normality 
test, all subpopulations passed normal distribution, with the exception of CD206highHLADRinter 
subpopulation.    
 
Differences in subpopulation frequencies across experimental conditions are shown in figure 3.8. 
CD206highHLADRinter subpopulations did not show significant differences in their frequencies over 
experimental conditions (Friedman test followed by Dunn’s multicomparison test). However, 
statistically significant differences were observed in CD206lowHLADRlow subpopulation 
frequencies between MCSF media alone and MCSF+IL-4+IL-13 (p=0.0427), and 
CD206lowHLADRinter subpopulation frequencies between MCSF media alone and 20% (v/v) 
NZM40 conditioned media (p=0.0012). No other significant differences were observed (RM one-
way ANOVA test followed by Tukey’s multicomparison test). Nevertheless, CD206highHLADRlow 
and CD206highHLADRinter subpopulations showed a trend towards an increase under both 20% 
(v/v) NZM40 conditioned medias, with or without 100𝜇M ascorbate supplementation, while 
CD206lowHLADRinter frequency appeared to decrease under the same conditions compared to the 
remaining experimental conditions. Moreover, CD206lowHLADRhigh subpopulations showed a 
trend towards an increase with 20% (v/v) NZM40 conditioned media with 100𝜇M ascorbate 
supplementation, CD206lowHLADRlow populations appeared to decreased under MCSF + LPS + 
IFN-𝛾 and MCSF + IL-4 + IL-13 medias, while CD206highHLADRhigh frequencies showed 
observable decreases under MCSF and 20% (v/v) NZM40 conditioned media with 100𝜇M 
ascorbate supplementation. All SEM error bars, in particular those found in values associated with 
MCSF + LPS + IFN-𝛾 and 20% (v/v) NZM40 conditioned media with 100𝜇M ascorbate 
supplementation, showed notable uncertainty around the mean, with the exception of the SEMs 
describing subpopulations treated with MCSF media. 
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Despite lack of statistical significance, an observable pattern is depicted in figure 3.8. Under MCSF 
media, CD206low/inter/highHLADRlow, and CD206low/inter/highHLADRhigh subpopulations can be found 
at similar frequencies, while CD206low/inter/highHLADRinter can be observed as the predominate 
phenotype. However, in the positive controls, CD206highHLADRhigh subpopulations appear to 
increase in frequency, first at the expense of CD206low/inter/highHLADRlow in MCSF + LPS + IFN-
𝛾, followed by CD206low/inter/highHLADRinter in MCSF + IL-4 + IL-13. Under 20% (v/v) NZM40 
conditioned media, CD206lowHLADRhigh subpopulations were not identified, and 
CD206low/inter/highHLADRlow, and CD206highHLADRinter frequencies increased at the expense of 
CD206low/interHLADRinter subpopulations. In contrast, a uniform distribution of 
CD206low/inter/highHLADRhigh frequencies can be observed under 20% (v/v) NZM40 conditioned 
media with 100𝜇M ascorbate supplementation, whereas CD206low/inter/highHLADRlow frequency 













































































































Figure 3.8: Presence of Different Subpopulations as a Total Percentage of CD68+CD206+HLADR+ 
Macrophage Populations. Derived from CD68+CD206+HLADR+ subpopulations, sorted from 
Macrophages cultured under different experimental conditions, these subpopulations can further be sorted 
depending on the intensity of markers present on cells. These intensities were categorized into CD206 
low, intermediate (inter) or high and HLADR low intermediate (inter) or high, and the combinations of 
these intensities, along with the presence of CD68, were used to sort into subpopulations. Data was 
obtained from N=3 healthy volunteers. The means of subpopulations over different experimental 
conditions are graphed as stacked bars, representing percentages of the total population. Different 
subpopulations can be identified by colour and SEM error bars are shown. RM one-way ANOVA with 
Geisser-Greenhouse correction followed by Tukey’s multicomparison test was performed on 
subpopulations across different experimental conditions. The exception was for 
CD68+CD206highHLADRinter, which were subjected to Friedman test followed by Dunn’s multicomparison 
test. Statistical significance is denoted * p≤0.05 and ** p≤0.005, representing CD206lowHLADRlow and 




3.5.  Measurement of Selected Gene Expression  
3.5.1.  Fold-Changes of Selected Gene Expression in Macrophages Treated with MCSF + LPS 
+ IFN-𝛾 and MCSF + IL-4 + IL-13 
 
Prior to RT-qPCR, RNA and primers were tested, and DNA/RNA extraction was optimised. 
Following PCR (section 2.11), poor-quality data was removed from the RT-qPCR analysis 
(Appendix 4.4). With clean CT data output, relative expression of selected genes under 
different experimental conditions was calculated against cellular expression under MCSF 
media, after being normalized by HPRT1 (section 2.11.2). The data failed to pass the Shapiro 
Wilk normality test, and therefore non-normal distribution was corrected for by log 
transforming the data, with all datasets then passing normality except TNF𝛼 expression under 
20% (v/v) NZM40 conditioned media.  
 
 MRC1 (p=0.0024), MMP-9 (p=0.0148), CCL-3 (p=0.0004) and IL-1𝛽1 (p=0.0007) were 
observed to exhibit statistically significance differences in expression between the 
experimental conditions, MCSF + LPS + IFN-𝛾 and MCSF + IL-4 + IL-13 (figure 3.9; paired 
two-tailed T tests). Moreover, a trend towards differential expression was observed in MMP-
2, CD163, TET2 and TNF𝛼, but these differences did not achieve statistical significance 
(Paired two-tailed T tests, unpaired two-tail T test and Wilcoxon test, respectively). The 
remaining genes showed similar expression under both positive controls. Furthermore, 
comparative to mean basal gene expression found in MCSF media (indicated by the dotted line 
in figures 3.9 and 3.10), some genes showed increased/decreased expression expected of the 
particular stimulation. This included MRC1 (encoding for CD206 and an M2-affiliated 
marker), which increased under MCSF + IL-4 + IL-13 and alongside, TGF𝛽1 and CD163, 
decreased in MCSF + LPS + IFN-𝛾. IL-1𝛽 and TNF𝛼 expressions increased under MCSF + 
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LPS + IFN-𝛾, and IL-1𝛽 decreased with MCSF + IL-4 + IL-13. High variability in expression 
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Figure 3.9: Relative Gene Expression of Cells Cultured with Either MCSF + LPS + IFN-𝛾 or MCSF + IL-4 + 
IL-13 Media Against Cells Cultured with MCSF Media. Normalized against HPRT1, selected genes expression 
in Macrophages grown under different experimental conditions was determined as a fold difference, compared 
to the genes expression in cells cultured in MCSF media. Log10 transformed data is plotted. Mean expression 
observed in MCSF media is set to 0 and represented by the dotted line, and data relating to experimental 
conditions can be identified by the assigned colour (see figure for details). Gene affiliation with M1 or M2-like 
phenotypes are stated. Mean lines are shown, along with SEM bars. Data was obtained from N=3-4 healthy 
volunteers. Paired two-tailed T tests were performed across values related to different experimental conditions 
for each gene. Exceptions were for TET2, which was analysed using an unpaired two-tail T test, and TNF𝛼, 
which was subjected to a two-tailed Wilcoxon matched-pairs signed rank test. Statistical significance is denoted 
* p≤0.05, ** p≤0.005, *** p≤0.001.     
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3.5.2.  Fold-Changes of Selected Gene Expression in Macrophages Treated with 20% (v/v) 
NZM40 Conditioned Media With or Without Ascorbate Supplementation 
 
No statistically significant differences were observed in relative expression of each gene when 
comparing between 20% (v/v) NZM40 conditioned media, with or without 100𝜇M ascorbate 
supplementation (figure 3.10) (Paired two-tailed T test or Wilcoxon test). However, a trend 
towards differential expression was observed in TGF𝛽1, CD163 and TET2. Comparative to 
basal expression under MCSF media, MRC1 and CCL-3 expression tend to increase under 20% 
(v/v) NZM40 conditioned media, while TGF𝛽1, IL10, MMP-9, TET2 and TNF𝛼 expression 
tend to decrease. Under 20% (v/v) NZM40 conditioned media with 100𝜇M ascorbate 
supplementation, MRC1 and CCL-3 showed an trend towards an increase in expression 
compared to MCSF media, while TGF𝛽1, IL10, MMP-9, CD163 and TNF𝛼 expression showed 
a trend towards a decrease with 20% (v/v) NZM40 conditioned media with 100𝜇M ascorbate 
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Figure 3.10: Relative Gene Expression of Cells Cultured Under 20% (v/v) NZM40 Conditioned Media With 
or Without 100𝜇M Ascorbate Supplementation Against Cells Cultured Under MCSF Media. Normalized 
against HPRT1, selected genes expression in Macrophages grown under different experimental conditions 
was determined as a fold difference, compared to the genes expression in cells grown in MCSF media. Log10 
transformed data is plotted. Mean expression observed in MCSF media is set to 0 and represented by the 
dotted line and data associated with different experimental conditions can be identified by colour (see figure 
key for details). Gene affiliation with M1 or M2-like phenotypes are stated. Mean lines are shown, along 
with SEM bars. Data was obtained from N=3-5 healthy volunteers.  Paired two-tailed T tests were performed 
across values related to different experimental conditions for each gene, with the exception of TNF𝛼, which 
received a two-tailed Wilcoxon matched-pairs signed rank test. No statistical significance was detected.         
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3.6.  Epigenetic Marker Measurement  
3.6.1.  Measurement of Selected Epigenetic Markers 
After concentrating DNA (table 5.1.1, Appendix 5.1) nucleotides were liberated and then 
analysed through mass spectrometry (section 2.8). Using standard curves for the markers of 
interest (figure 5.2.1, appendix 5.2), unknown concentrations from the mass spectrometry 
output were calculated and transformed to a percentage of total cytidine. No statistically 
significant differences were observed in the percentages of total cytidine that deoxycytidine, 
methylcytidine and hydroxymethylcytidine groups acquire when the cells were cultured under 
different experimental conditions (figure 3.11) (RM one-way ANOVA test followed by 
Tukey’s multicomparison test). However, changes in the presence of all epigenetic markers 
across experimental conditions can be observed. Moreover, plotted values for deoxycytidine 
and methylcytidine, derived from MCSF, MCSF + LPS + IFN-𝛾 and 20% (v/v) NZM40 
































































































Figure 3.11: Presence of Methylcytidine and Hydroxymethylcytidine as a Total Percentage of Cytidine 
When Cells are Grown Under Different Experimental Conditions. Concentrations from mass spectrometry 
output values were calculated from standard curves and converted to a percentage of total cytidine. Data was 
obtained from N=5 healthy volunteers. The percentage of deoxycytidine, methylcytidine and 
hydroxymethylcytidine as a total percentage of cytidine is represented as stacked bars, with the mean and 
SEM bars graphed. The different markers can be identified by colour. RM one-way ANOVA with Geisser-
Greenhouse correction, followed by Tukey’s multicomparison test with individual variance, was conducted 
on each population across the different experimental conditions. No statistical significance was detected.              
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Using the previously generated percentage values of deoxycytidine, methylcytidine and 
hydroxymethylcytidine as a total proportion of cytidine, statistical tests were performed on the 
values derived from Mϕ cultured with either 20% (v/v) NZM40 conditioned media or 
conditioned media with 100𝜇M ascorbate supplementation (Paired one-tail T test). From these 
tests, statistically significant differences were not detected in either deoxycytidine or 
methylcytidine groups (figure 3.12). However,  hydroxymethylcytidine showed a strong trend 
towards an statistically significant increase in  20% (v/v) NZM40 conditioned media with 
100𝜇M ascorbate supplementation (p=0.0525), compared to the markers levels in 20% (v/v) 













































































20% (v/v) NZM40 Conditioned media 20% (v/v) NZM40 Conditioned media
 + 100μM Ascorbate
Figure 3.12: Cellular Deoxycytidine, Methylcytidine and Hydroxymethylcytidine Levels when Cultured in 
NZM40 Conditioned Media with or without 100𝜇M Ascorbate Supplementation. Concentrations from mass 
spectrometry output values were calculated from standard curves and converted to a percentage of total 
cytidine. Data was obtained from N=6 healthy volunteers. Deoxycytidine, methylcytidine and 
hydroxymethylcytidine as a percentage of total cytidine are graphed as a box and whiskers graph, with the 
whiskers showing the minimum and maximum of data points, the top and bottom of the box representing the 
25 and 75 percentiles of the data, and the line indicating the mean. Individual values can be observed within 
each box and whiskers. Data relating to different experimental conditions can be identified by colour. Paired 
one-tail T tests were performed across the values associated with the different experimental conditions, for 
each marker. Statistical significance is p≤0.05.   
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Chapter 4 - Discussion: 
In New Zealand, ~2,200 people are diagnosed and ~350 people die annually from Melanoma. The 
cancer remains the third most common cancer-diagnosis within the county. (5) Treatment for 
melanoma includes immunotherapy, such as Pembrolizumab, an anti-PD1 drug, which is primarily 
used in Christchurch hospital, New Zealand (128). This therapy, aimed at reactivating suppressed 
cytotoxic T cell responses, has provided treatment to patients who previously had poor outcomes 
(17). However, only 20-30% of patients show progression free survival (PFS) after 5-years of 
treatment, with the majority experiencing immune-related adverse events (irAEs) (18). Many of 
these irAEs are induced by the inflammatory cascade evoked by immunotherapies (20).  While 
irAEs are commonly treatable, if severe (grade 3-5) they can result in morbidity and mortality 
(129). Moreover, these inflammatory cascades could promote malignancy of tumours, providing 
the capability of metastasis (20, 130). Therefore, could the generation of mixed phenotype innate 
populations, i.e., Mϕs, provide the necessary brakes on inflammation cascades, limiting severe 
irAEs as well as the promotion of malignancy. This study set out to investigate this question, 
building on previous work conducted by Ang and colleagues, who generated mixed-phenotype 
Mϕ populations in mice with ascorbate supplementation (45). Furthermore, a particular focus of 
the current study was TET2, a demethylase that exerts an immunomodulatory role and possibly 
impacts Mϕ heterogenicity (71, 106, 108, 120, 121).    
 
4.1.  Can a Simple Artificial Melanoma Microenvironment be Derived from the Supernatant of 
Tumour Cells?  
To conduct this study in a Melanoma setting, a tumour microenvironment had to be fabricated 
for the culture of isolated peripheral blood-derived monocytes. Using transcriptomic data 
provided by Professor Bruce Baguley (table 6.1, appendix 6.1.1) the invasive melanoma cell 
lines NZM9, NZM40 and non-invasive cell line NZM42 were selected on merit of their Colony 
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Stimulating Factor 1/2 (CSF1/2) and IL-34 expression. These genes were of interest as the 
produced ligands mediate maintenance and differentiation of Mϕs through interacting with the 
CSF-1R receptor (131). The cell culture supernatant (conditioned media) from these cells was 
harvested and introduced to isolated monocytes at 20% or 40% concentrations. 
Monocytes/Mϕs only thrived in the conditioned media derived from the NZM40 cell line when 
present at 20% concentration (figure 3.1). This likely reflects the cell line’s higher expression 
of CSF1/2 and IL34, and at 20% concentration monocytes/Mϕs are receiving the necessary 
nutrients provided by the fresh cell culture media. Moreover, MCSF, a growth factor, was 
supplemented to the positive experimental controls, as normal growth media without MCSF, 
the negative control, resulted in inadequate growth (132, 133). However, confirmation of this 
explanation for minimal growth will likely require growth curve assays, with variables 
consisting of different concentrations and combinations of the highlighted factors.  
 
To further model a tumour microenvironment, cells were cultured with conditioned media at 
5% O2, reflecting oxygen levels that would commonly be found within normal tissue (134). 
Characterisation of gene expression and surface marker frequencies (section 4.5 and 4.6) from 
the monocytes/Mϕs cultured with 20% (v/v) NZM40 conditioned media revealed mixed Mϕ 
phenotypic profiles were revealed, neither directly M1- or M2-lineage affiliated. This suggests 
that the NZM40 conditioned media was not sufficient in generating M2-like TAMs. These 
results are surprising as the NZM40 cell line, among others, was selected on account of their 
IL10, TGF𝛽1 and IL-13 expression, cytokines that have previously been affiliated with the 
generation of M2-like phenotypes. (38) However, assays such as ELISAs will be required to 
measure the cytokine concentrations present within the cell line conditioned media before any 
conclusion can be made. It should also be noted that the melanoma model produced was 
simplistic when compared to an in vivo tumour microenvironment, meaning that the provided 
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stimulus may have been insufficient to differentiate peripheral monocytes to a clear M2-like 
Mϕ phenotype (22).  
 
4.2.  What is the Appropriate Concentration for Ascorbate Supplementation?                 
Typically, when ascorbate plasma levels are optimal (≥50𝜇M), intracellular concentrations within 
monocytes can be found around 3mM (114-116). Results from this study showed intracellular 
ascorbate concentrations of 0.31-1.147mM in donor PBMCs (figure 3.2). Since monocytes only 
make up 15% of the PBMC population, true comparisons cannot be made (127).  
 
Three concentrations, 100𝜇M, 200𝜇M and 400𝜇M were tested for ascorbate supplementation, and 
100𝜇M was found to induce adequate ascorbate uptake. In humans, physiological plasma ascorbate 
saturation occurs around 80𝜇M, meaning that the use of 100𝜇M would mimic a physiological limit 
achievable in patients (114). Therefore, 100𝜇M ascorbate was selected as a suitable concentration 
for ascorbate supplementation to the in vitro melanoma model. 
 
4.3.  Do Monocytes Transition to Macrophages with NZM40-Derived Conditioned Media? 
CD14 and CD68 are classical markers of monocytes and Mϕs (66, 89-93). The majority of 
monocytes, classical and intermediate monocytes, express CD14 at high levels, while the 
remaining subpopulation, non-classical monocytes, continue to express CD14, but at lower levels 
(89). As monocytes enter tissue, differentiation into Mϕs or DCs occurs, and as CD68 can be used 
as a robust marker for the Mϕ lineage, this surface marker was used for the identification of Mϕs 
(66). CD68 can be found on both monocytes and Mϕ, but during differentiation, expression of 
the surface marker has been observed to increase (92, 93). Within this study, the presence of 
CD68+ populations increased and CD14+ populations decreased as the cells were cultured for seven 
days under the positive control experimental conditions (figure 3.4 and 3.5). However, populations 
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cultured with 20% (v/v) NZM40 conditioned media, with or without ascorbate supplementation, 
did not show a shift towards CD68+ populations at day seven. One possible explanation is the 
increased presence of DCs, which do not possess the CD68+ marker and will therefore skew the 
analysed CD14+:CD68+ ratio (66). Moreover, some cells may co-express CD14 and CD68 (90-
92). Evidence for this exists with figure 3.6, with only approximately 10% of the total cell 
population not being identified with CD68 staining, over all experimental conditions. Therefore, 
results from this study suggest that NZM40-derived conditioned media, along with positive 
controls, were successful in stimulating the differentiation of monocytes to Mϕs.  
 
4.4.  Can Ascorbate Supplementation Enhance the Activity of TET2?  
Epigenetic modification enables the differentiation and plasticity observed within immune cells, 
increasing or decreasing chromatin accessibility, and so including or excluding transcriptional 
machinery from promoters during gene expression. Epigenetic modification is a dynamic process, 
changing the transcriptional landscape depending on the stimuli that a cell receives, and is 
dependent on epigenetic modifiers such as TET2. (44) Serving as an epigenetic eraser of DNA 
methylation, TET2 increases the accessibility of transcriptional machinery to promoters, inducing 
gene expression. From this mechanism, a by-product of TET2 activity is the generation of 5-
hydroxymethylcytosine, which can be measured to reflect the activity of the demethylase. (40, 72)       
 
Multifactorial comparison analysis revealed no statistical significance in the fluctuation of TET2 
activity over the experimental conditions (figure 3.11 and 3.12). However, using the more 
powerful one-tail paired T test (only possible as the results of this experiment were predicted 
beforehand), and with a greater N value of 6, a p-value of 0.0525 was generated for the pairwise 
comparison of hydroxymethylcytidine levels in 20% (v/v) NZM40-derived conditioned media 
with or without 100𝜇M ascorbate supplementation. This indicates that ascorbate supplementation 
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does increase TET2 activity, and reflects the role of ascorbate as a co-factor for the demethylase 
(72, 73, 75). However, it should be noted that the increased presence of hydroxymethylcytidine 
may also be the result of TET1 and/or TET3, as these enzymes also possess demethylation activity 
similar to TET2 in Mϕs (71, 76, 100, 135, 136). Knocking out TET1 and TET3 activity, possibly 
with designed small interfering RNA (siRNA), would provide a more accurate measurement of 
TET2 activity, but due to expense, difficulty and time, complete Mϕs were analysed within this 
study (135, 137, 138).  
 
4.5.  Does NZM40-Derived Conditioned Media Shift Gene Expression and can Ascorbate 
Supplementation Modify this Shift? 
Previous work conducted by Ang and colleagues in a murine model revealed that ascorbate 
supplementation resulted in the generation of a mixed-phenotype population of murine Mϕs, 
displaying upregulation and downregulation of genes typically associated with M1- and M2-like 
lineages (45). With ascorbate supplementation, the analysed cells showed an upregulation of 
classical M2-associated genes, ARG1 and VEGFA, along with a downregulation of TGF𝛽1 and 
Ym1, while IL-6 was upregulated and TNF-𝛼 was downregulated, classical M1-associated genes 
(45). In the current study, I aimed to investigate whether these results translate to human Mϕs.  
 
MCSF + LPS + IFN-𝛾 and MCSF + IL-4 + IL-13 were used as positive controls to shift Mϕs 
towards M1- and M2-like phenotypes, respectively (139, 140). This can be seen in figure 3.9, 
which shows an upregulation of CCL-3, TNF𝛼, IL-1𝛽 (M1 markers) and TET2 under MCSF + 
LPS + IFN-𝛾 conditions, while MRC1 (an M2 marker) was upregulated in MCSF + IL-4 + IL-13 
media. However, classical M2 markers TGF𝛽1, IL10, MMP-9 and CD163 did not exhibit an 
increase of expression with IL-4 + IL-13 media (see section 1.3.2. for gene description). A possible 
explanation could relate to the duration of stimulation, with M2-like markers requiring 4-72hrs for 
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peak expression, whereas M1-like markers require around 4hrs. This may also provide reason for 
the lack of statistically significant differences in gene expression over the positive controls, with 
the exception of MMP-9, MRC1 and IL-1𝛽. Once peak expression has been achieved, it can begin 
to decrease without continued stimulation, e.g., TNF𝛼 expression tends to decrease after peaking 
at approximately 4hrs. (141) The study conducted by Purcu and colleagues detailing this 
information was released during July 2021, well after experimental procedures had commenced, 
meaning that incorporation of the appropriate stimulation times could not be performed in this 
study. Alternatively, endotoxin contamination may have occurred, skewing the results, or genes 
outside the scope of the analysed panel may be influencing the observed expression profile. For 
example, LPS + IFN-𝛾 stimulation could cause the upregulation of IL-6 and IL10, a 
proinflammatory and anti-inflammatory cytokine, respectively (58, 141). While these genes may 
have opposing functions, IL-6 could be addressing the inflammatory stimuli, while IL10 is 
upregulated to limit an inflammatory cascade and/or in preparation for the response that follows – 
the resolution of inflammation. Transcriptomic analysis would be required to fully analyse the 
expression of Mϕ	genes under the various experimental conditions. 
 
With NZM40-derived conditioned media, the relative expression of CCL-3 and MRC1 (encoding 
for CD206) (M1 and M2 markers, respectively) increased, while a decrease in expression was 
observed for TNF𝛼 (M1 marker) TGF𝛽1, IL-10, MMP-9 (M2 markers) and TET2, compared to 
expression levels found in MCSF media (figure 3.10). These expression fluctuations tend to follow 
those observed in the MCSF + IL-4 + IL-13 control, with the exceptions of TNF𝛼 and IL-𝛽1, which 
showed decreased and increased expression, respectively. These divergences may be the result of 
several mechanisms, including epigenetic modification altering the promoter accessibility during 
transcription (44). Overall, a mixed expression signature was identified, neither truly reflecting a 
M1- or M2-like expression profile, as both M1- and M2-affiliated genes were upregulated and 
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downregulated (52, 53, 58, 59, 64, 65). This comes with little surprise as TAMs exist as 
heterogeneous populations, comprising of varying expression profiles. (51) However, as the model 
was designed to use melanoma cell conditioned media to generate Mϕs that leaned heavily towards 
M2-like phenotypes, a feature commonly found within TAMs, the gene panel used in this study 
indicated that 20% (v/v) NZM40-derived conditioned media was not sufficiently successful in 
generating a M2 expression profile (38, 48).   
 
With ascorbate supplementation to the NZM40-derived conditioned media, further decreases in 
TGF𝛽1 and CD163 expression were observed (figure 3.10), while TET2 appeared to increase in 
expression. Although no statistically significant differences between the two groups were detected, 
these alterations in TGF𝛽1 and CD163 expression may reflect a changing epigenetic landscape, 
with transcriptional machinery/transcription factor competition from other open gene promoters 
resulting in the downregulation of these genes (142). This agrees with the increase in TET2 
expression and activity observed in this study. Moreover, as ascorbate is a co-factor for the activity 
of TET2, supplementation may have given rise to the gene’s upregulation, through reducing TET2 
regulatory pathways, such as microRNA Let-7adf, which directly inhibits the expression of TET2 
(143). However, further testing would be required to investigate these explanations. In the current 
study, ascorbate supplementation had minimal impact on shifting gene expression. However, due 
to the melanoma model’s limitations in generating a clear M2-like expression profile, ascorbate’s 
true capability in inducing a mixed expression profile warrants further investigation.   
 
4.6.  Does NZM40-Derived Conditioned Media Modify Cellular Functional Phenotypes and can 
Ascorbate Supplementation Alter this Modification? 
The presence and combination of surface markers on a cell provide further information on the cell’s 
functional phenotype. Three functional phenotypes were examined in this study, 
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CD68+CD206+HLADR+, CD68+CD206+HLADR- and CD68+CD206-HLADR+, and two more 
phenotypes, CD68+CD206-HLADR- and CD68- were measured. With the presence of CD68 
indicating Mϕ lineage, and HLADR and CD206 representing M1 and M2 markers, respectively 
(96).  
 
Populations cultured with the positive control media MCSF + LPS + IFN-𝛾 showed an increase in 
CD68+CD206+HLADR+ and CD68+CD206-HLADR+ phenotypes, whereas MCSF + IL-4 + IL-13 
reflected an increase of CD68+CD206+HLADR- phenotype, comparative to populations cultured 
under MCSF growth media (figure 3.6). While these differences are not statistically significant, 
they do show a trend towards phenotypic change towards the respective M1-like and M2-like 
profiles. NZM40-derived conditioned media further upregulated CD68+CD206+HLADR- 
phenotype frequency, while conditioned media with 100𝜇M ascorbate supplementation resulted in 
an observable increase in the CD68+CD206+HLADR+ populations. The upregulation of CD206 
markers under MCSF + IL-4 + IL-13 and NZM40-derived conditioned media agrees with the 
qPCR results (section 4.5). However, Mϕs derived from NZM40-derived conditioned media did 
not show a upregulation of MRC1 (CD206) gene expression, compared to Mϕs from IL-4 + IL-13 
media, and yet the surface marker CD206 showed a trend towards an increase. A study using the 
‘squared Pearson correlation coefficient’ describes that expression profiling can only offer 
explanatory power to ~40% of a protein’s variance, indicating that protein degradation and other 
underlying translational negative regulation pathways impact protein levels, e.g., CD206 presence 
(45, 108, 144-148).  
 
Drilling down into the examined functional phenotypes, the level of marker presence on a cell was 
assayed using relative intensity of immunosignal. From CD68+CD206+HLADR- populations, the 
positive controls, MCSF + LPS + IFN-𝛾 and MCSF + IL-4 + IL-13 both induced near identical 
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subpopulations of CD206low/inter/high cells (figure 3.7 A). This is unusual as IL-4 + IL-13 was 
expected to generated high frequencies of CD206inter/high subpopulations, compared to LPS + IFN-
𝛾. However, this may reflect MRC1 (CD206) transcripts competing for translational machinery 
with other genes that are being expressed at variable levels in the population (149). Interestingly, 
in cells cultured with NZM40-derived conditioned media, CD206high became the dominant 
phenotype of CD68+CD206+HLADR- cells. However, with ascorbate supplementation, 
subpopulation phenotype frequency returned to a similar pattern found in both positive controls. 
These results may be due to ascorbate supplementation and positive controls, but not NZM40-
derived conditioned media, inducing regulatory pathways that modulate CD206 protein. However, 
to the best of my knowledge, a specific regulatory pathway for CD206 protein has yet to be 
identified. This downregulation of CD206 could be of clinical importance, as increased CD206 
expression in Mϕs have previously been correlated with reduced survival in patients with various 
solid tumours (150).   
 
Within CD68+CD206-HLADR+ populations (figure 3.7 B), the positive controls could not be 
compared, as one volunteer failed to produced CD206-HLADR+ cells under MSCF + LPS + IFN-
𝛾 media. This skewed the results and resulted in the population stack not achieving 100% (see 
section 4.8 below for discussion). All donors failed to generate CD206-HLADR+ cells with NZ40-
derived conditioned media, however, with ascorbate supplementation, CD206-HLADR+ 
phenotypes were produced. This could suggest that ascorbate upregulated the activity of an 
epigenetic modulator, which enabled the expression of HLADR in the tumour model (116). These 
results are in concordance with the observed increase in the presence of 5hmC (section 4.5), 
indicating that a TET family member could be responsible for the shifts of CD206 and HLADR 
subpopulations within CD68+CD206+HLADR- and CD68+CD206-HLADR+ cells. Illumina 
methylation arrays would provide more information regarding this explanation, as it can show the 
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methylation status of different individual CpG sites (151). Nevertheless, this upregulation of 
HLADR was of particular interest, as CD14+HLADRhigh monocytes were previously correlated 
with enhanced response to anti-PD1 immunotherapy, suggesting a possible role of HLADR in 
improved patient outcomes (152).        
 
In CD68+CD206+HLADR+ cells, subpopulation frequencies across the positive controls are similar 
to one another (figure 17). This is surprising, as an upregulation of 
CD68+CD206low/inter/highHLADRlow and CD68+CD206lowHLADRlow/inter/high subpopulations was 
expected in MCSF + LPS + IFN-𝛾 and MCSF + IL-4 + IL-13 media, respectively. Again, one 
explanation could be competition for translational machinery, but further testing is required (44, 
149). Subpopulation frequencies across NZM40-derived conditioned media, with or without 
100𝜇M ascorbate supplementation, were also similar, with the exception of CD206highHLADRhigh 
and CD206lowHLADRhigh phenotypes, which appeared to increase in frequency in the respective 
medias. Similar to previous findings, HLADR upregulation could be due to ascorbate 
supplementation enhancing the activity of TET2, which is supported by the increased 5hmC 
presence (108, 148).  However, further investigation would be required to add confidence to this 
explanation. 
 
Analysis of cellular phenotype frequencies with the current panel of surface markers, suggest that 
NZM40-derived conditioned media could be capable in generating M2-dominant phenotypes, 
identified by the upregulation of the frequency and intensity of the CD206 marker. This was not 
without the presence of HLADR though in some circumstances, indicating the presence of mixed-
phenotypes within the population. With ascorbate supplementation, HLADR was upregulated, 
indicating a further shift towards a more heterogenic population, as many cells continue to display 
CD206 markers. These results were not surprising, as Mϕs are plastic cells that are capable of a 
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spectrum of activity, and with ascorbate supplementation this may have further opened up the 
epigenome, allowing more expression and greater heterogenicity (39, 44, 116). Although no 
statistically significant differences in phenotype frequency were detected between the two 
conditioned media groups (with or without ascorbate 100𝜇M supplementation), the relative 
downregulation of CD206 and upregulation of HLADR observed on Mϕs could be of clinical 
significance. This is due to Mϕs with these phenotypes being previously associated with improved 
immunotherapy response and overall survival outcomes (150, 152).      
 
4.7.  Strengths and Limitations of this Study       
The strengths and limitations of the experimental model, protocols, capability and analysis are 
discussed in the following subsections. Troubleshooting experiments are referred to, but are 
detailed within the appendices, e.g., Appendix 4.        
 
4.7.1.  Melanoma Model 
The melanoma model produced was simplistic in comparison with an in vivo tumour, as it does 
not represent the complexity of an interacting network of cells and extracellular matrix found 
within a tumour microenvironment (22). Moreover, the model cannot mimic the temporal and 
spatial heterogeneity of transformed cells (24). To mitigate these problems, several melanoma 
cell lines were selected to increase the representation of the model compared to an in vivo 
melanoma. However, as only one cell line (NZM40) was successful in supporting 
monocyte/Mϕ growth, the reduced representation became a limitation of the study. Cells were 
cultured with conditioned media at 5% O2, levels that would commonly be found within 
physiologically normal tissue. Although this may not reflect oxygen levels found in tumours, 
which may be <1%, this does more closely mimic the tumour microenvironment than ambient 




To enrich for peripheral blood-derived monocytes exposed to the melanoma model, the procedure 
relied on the cells adhesive capabilities. This could be a potential limitation to the protocol, as 
contamination with other cells may have impacted the differentiation of monocytes, e.g., CD8𝛼+ 
dendritic cells produce type I interferons, which could favour monocyte differentiation into 
M1-like phenotypes (29, 139). Moreover, a subset of monocytes that possess greater adhesive 
properties, alongside other characteristics, may have been actively selected for, reducing a true 
representation of the volunteers monocyte populations. To mitigate these possible limitations, 
magnetic bead kits could be used to isolate monocytes, but these are relatively expensive 
compared to the protocol utilised in this study (153).               
 
4.7.2.  Ascorbate Measurement 
When determining the optimal ascorbate concentration to supplement NZM40-derived conditioned 
media, low yields of cells were extracted from the cultured plates. This became a limitation to the 
protocol, as the countable range was below 25 within the hemacytometer. This introduced error 
into the estimated population size – a limitation of the study as the final ascorbate concentration 
was presented as nMoles per million cells. Moreover, after cell lysate was produced from the cells, 
the sample was not reduced. This would have provided opportunity for ascorbate oxidization and 
subsequent degradation, reducing the measured concentrations (154). To minimise possible 
degradation, samples would be reduced in future experiments. However, HPLC has the advantage 
of excellent sensitivity, having an ascorbate detection limit of approximately 1.032𝜇g/mL, and the 






4.7.3.  Measuring Monocyte to Macrophage Transition  
Conclusions for this experiment were difficult to draw due to limitations in the experiment, which 
included only a N=1 being achieved for some experiments. This was due to the level 4/3 COVID-
19 lockdown imposed by the New Zealand (NZ) Government, and meant that statistical analysis 
could not be performed on this experiment and only suggestions of relationships could be made. 
Repeats of this experiment will be required in the future. Furthermore, CD14+:CD68+ ratios were 
derived from crude comparisons, as the antibodies against CD14 and CD68 markers were of the 
same host species. This meant that populations on the same plate had to be stained with either 
CD14 or CD68, resulting in the ratios being derived from two populations cultured under the same 
experimental conditions. To correct for this, CD14- and CD68-directed antibodies from different 
host species should be purchased for downstream repeats. However, this experiment did allow for 
the confirmation of Mϕ transition, utilising minimal resources, time and cost.  
 
4.7.4.  Measuring TET2 Activity   
The true extent of TET2 activity may be concealed within the recorded deoxycytidine frequencies, 
limiting the accuracy of the experiment. This is possible as TET2 can oxidise 5-
hydroxymethylcytosine into 5-formylcytosine and 5-carboxycytosine (71, 72, 100). Moreover, 5-
hydroxymethylcytosine can be directly excised and replaced by unmethylated cytosine, or removed 
during DNA replication (101-104). This is reflected in figure 3.12, with cells cultured with 
NZM40-derived conditioned media + 100𝜇M ascorbate supplementation showing higher 
deoxycytidine levels, compared to those cultured with no supplementation. Thus, to improve 
accuracy in the measurement of TET2 activity, 5-formylcytosine and 5-carboxycytosine could be 
included into the assay. Nevertheless,  mass spectrometry enables genome wide analysis of 
epigenetic markers, a powerful tool in this study (156). Moreover, the current measurement of 
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hydroxymethylcytidine provides sufficient insight into TET2 activity, without the cost of additional 
markers.   
 
4.7.5.  Measuring Gene Expression 
Unfortunately, several primers, including those designed for ARG1 and IL-6, failed to induce 
amplification of their respective gene products. Moreover, despite producing PCR products, genes 
such as VEGFA were removed from analysis, as their products melting curves showed several non-
specific amplifications. These failures may relate to the initial quality of the RNA. Detailed in 
Appendix 4.4 and shown in figure 4.4.1 A, partial degradation of RNA is apparent, providing a 
possible explanation for the PCR failures. If the RNA had degraded prior to cDNA generation this 
could have resulted in failure of amplification, or the amplification of partial products, depending 
on the extent and/or region of degradation. A study conducted by Imbeaud and colleagues found 
that even with slight RNA degradation, relative expression can vary by up to 7-fold (157). 
Moreover, the obtained A260/A230 ratios, shown in table 7.1 of appendix 7.1, fall below the 
acceptable ~2 threshold. This is likely due to organic contamination. (158, 159) Currently, no 
literature to the best of my knowledge discusses how low A260/A230 ratios will compromise PCR 
reactions, with some studies indicating that contamination may have little effect on downstream 
experiments (160, 161). However, it has been observed that with minimal phenol contamination, 
the recorded RNA concentrations were skewed. Therefore, forms of organic contamination could 
have resulted in inadequate RNA concentrations being supplied for cDNA synthesis, which would 
have downstream consequences for RT-qPCR and analysis. (162)   
 
RT-qPCR offers a cost-effective sensitive technique for gene expression quantification (163, 164). 
However, the technique does come with limitations, including specificity, with the amplification of 
non-specific or incomplete products, generation of primer dimers and reliance on the generation of 
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good quality cDNA for the analysis of gene expression (165). This process offers opportunity for 
contamination and depends on good quality RNA, which can be prone to degradation. These 
limitations may have impacted the quality of the conducted RT-qPCR for this experiment and have 
possibly influenced results, reducing confidence in the output data. (157, 162) To help minimise 
these limitations, TaqMan probes could be used in the assay, providing greater specificity. 
However, as TaqMan probes can be expensive, RT-qPCR with EvaGreen was utilised. (166)       
 
4.7.6.  Measuring Functional Phenotypes Using Cell Surface Markers 
Limitations in measuring functional phenotypes with cell surface markers include a low biological 
replicate of 3 (due to NZ level 4/3 COVID-19 lockdown), which reduced power in any statistical 
analysis. Additionally, using only two surface markers for the identification of Mϕ phenotypes is 
a limiting factor. Due to the plastic nature of Mϕs, two markers are inadequate to accurately portray 
a phenotype that resembles the functionality of a cell  (43). However, as this was a pilot study, two 
markers were sufficient to indicate the possible M1/M2 profiles that the cells were shifting towards. 
Furthermore, while flow cytometry would have enabled a more accurate analysis of populations 
and subpopulations, this form of measurement requires cells in liquid suspension (167). Achieving 
sufficient yields would have been particular difficult, due to Mϕs adhesive capabilities (168). 
Immunocytochemistry allowed for direct measurement on the cultured plates, providing a key 
strength to the protocol.     
 
 4.7.7. P-values 
P-values have served as the gold standard for determining the significance of data within the 
scientific community, but arguments against using standard p-value cut-points are rising. Key 
arguments include that with a large enough sample size statistical significance may be detected 
regardless of true difference, and reproducibility is limited with p-values below 0.05 having a 
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1 in 3 chance of being a type 1 error. (169) Limited information on biological relevance is also 
provided by p-values, as differences that were identified to be non-significant may exert a 
butterfly affect at a whole biological system level. However, the p-value does currently provide 
standardization of statistical significance among the scientific community (169). Within this 
study, p-values were used to determine statistical significance, but observable differences in 
data were also discussed.       
 
4.8.  Heterogeneity Across Donor Monocytes/Macrophages 
Across all experiments SEM error bars and gene expression distribution were notably extended, a 
factor that likely reduced statistical significance within the obtained results. This was surprising, as 
unlike standard deviation which does measure variability, SEM reflects the accuracy of the 
presented data mean (170). This indicates high variability of data between volunteers, in turn 
impacting the precision of the mean. Relating to this study, such heterogeneity in data may be due 
to several reasons, including contamination, differing initial epigenomic landscapes and previous 
innate training/tolerance.     
 
The most simplistic reason for the observed heterogeneity is contamination of the samples. While 
steps were taken to minimise contamination from sources such as endotoxins, this does not remove 
the possibility of their presence. If true, this would have prematurely activated the cells, resulting 
in a heightened, differential response, expression and functional phenotype, compared to cells that 
were not exposed to contamination. Procedures could be put in place to further minimise this, 
including more frequent testing of milliQ water for endotoxins, or using commercially available 




Previously, ascorbate has been discussed in the context of enhancing the activity of different 
epigenetic modulators (116). Acknowledging this, it can be proposed that volunteer 
monocytes/Mϕs may have different epigenomic status in accordance with the range of initial 
intracellular concentrations of ascorbate within immune cells. For example, volunteer A produced 
a 9.58 fold-change in TNF𝛼 expression when cells were cultured with MCSF + IL-4 + IL-13 
media, compared to the 5.82 fold-change observed in volunteer B. Respectively, these volunteers 
were found to exhibit intracellular ascorbate concentrations of 1.147 and 0.869 nMoles per million 
cells. This serves as an example of the many differences observed between volunteers.  
 
An alternative explanation could derive from innate training/tolerance. Currently, there is growing 
evidence that shows the innate immune system has a de facto memory of past stimuli, which can 
alter response to a second immune stimulus (171-173). This form of memory derives from 
epigenetic and metabolic reprogramming of myeloid lineage cells, and their progenitors, allowing 
for long-lasting changes that can lead to suppressed or enhanced innate response to secondary 
stimuli - processes termed ‘tolerance’ or ‘training’, respectively. (172-174) Previously, such 
reprogramming has been associated with attenuated vaccines including the Bacillus Calmette-
Guerin (BCG) vaccine (175). Relating to this study, volunteer D had recently received the 
Pfizer-BioNTech COVID-19 vaccine and exhibited a 111.69 fold-change in IL-1𝛽 expression, 
when cells were cultured with MCSF + LPS + IFN-𝛾 media, compared to the 60.13 fold-change 
observed in volunteer A. This suggests that recent vaccination could have primed the 
monocytes prior to stimulation with cytokines, resulting in enhanced expression. Further 
testing is required to confirm this, but this could provide an explanation to some of the notably 
extended SEM bars. In future studies, this could be corrected for by further standardizing the 
healthy volunteers, by recent vaccination and history of illness, or increasing sample size to 




4.9.  Future Directions of this Study 
The immediate next steps following this study would be to establish a co-culture model with the 
NZM40 cell line, and possible additional melanoma cell lines, and peripheral blood-derived 
monocytes. This would allow bi-directional communication between the melanoma cells and 
isolated monocytes, which will more closely mimic the tumour microenvironment. Once 
confirmed using the protocols described in this study, ascorbate supplementation would be 
provided and the question of whether ascorbate can alter TAMs into heterogenic populations in a 
human model would be re-evaluated. Furthermore, the gene and cell surface marker panel could 
be expanded in future experiments, providing a stronger indication of the cell’s functional 
phenotype.  
 
To provide strong evidence that the shift of Mϕ phenotype is biologically relevant, functional 
assays would be conducted. These assays could investigate the following: 1) cell migration using 
a transwell assay involving the NZM40 melanoma cell line and differentiated macrophages, 2) 
matrix degradation potential using zymograms conducted on the supernatant of Mϕ cultures, 3) T 
cell activation/suppression through co-culturing lymphocytes with macrophages and observing the 
rate of proliferation with flow cytometry, 4) cytotoxicity assays co-culturing Mϕs with the 
melanoma NZM40 cell line, followed by a propidium uptake assay, and 5) secreted factors 
identified through conducting NMR and subsequent ELISA assays against a selected panel of 
cytokines and chemokines. Together, these assays would provide valuable information on the 
functional capabilities of heterogenic Mϕ populations, indicating whether ascorbate 




Additionally, further studies could investigate TET2’s capability of oxidizing mRNA methyl 
markers, and how this could affect downstream proteins and/or pathways (108). For example, if 
TET2 is found to regulate Socs3 in TAMs, and if a downstream target of an upregulated JAK/STAT 
pathway is HLADR, this could directly associate TET2 with the regulation of TAMs phenotype 
(108, 148). Thus, providing evidence for one mechanism of action for how ascorbate 
supplementation could shift TAMs to a more heterogenic form.          
 
4.10.  Conclusions       
This study was conducted to investigate whether an in vitro melanoma model could be developed 
using the supernatant produced by NZM melanoma cells lines, and whether ascorbate 
supplementation to this tumour model could shift human TAMs towards a more heterogenic 
population. Moreover, particular emphasis was made on TET2, due to the enzyme’s 
immunomodulatory role.  
 
The in vitro melanoma model, using 20% (v/v) NZM40-derived conditioned media, was successful 
in supporting monocyte/Mϕ growth, but did not stimulate clear monocyte differentiation towards 
M2-like phenotypes. Profiling the gene expression of cultured Mϕs revealed an expression 
signature that was neither truly affiliated with M1- or M2-like lineages. However, analysis of cell 
surface markers showed the tumour model did induce CD206 (an M2 marker) dominated 
subpopulations, which was supported by qPCR findings showing higher MRC1 expression in 
NZM40 conditioned media cultured Mϕs compared to MCSF only. With 100𝜇M ascorbate 
supplementation, the presence of HLADR+ (an M1 marker) subpopulations increased, whereas 
CD206 protein expression decreased, supporting the concept that ascorbate is capable of modifying 
Mϕ phenotype. Moreover, these shifts in cell surface protein expression concurred with the 
increase in demethylation observed with ascorbate supplementation, indicating increased TET2 
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activity. In patients receiving treatment for advanced melanoma, upregulated Mϕ HLADR protein 
expression has previously been associated with improved anti-PD1 immunotherapy  response, and 
downregulation of CD206 has been associated with greater overall survival of patients with various 
solid tumour types (150, 152). If ascorbate supplementation generates a more favourable mixed 
TAM phenotype, this may provide a rationale to supplement melanoma patients receiving 
immunotherapy with ascorbate. Particularly, as patients with advanced melanoma receiving 
immunotherapy have been shown to have very low plasma ascorbate concentrations (117). 
 
In summary, this pilot study provided some evidence to support the concept that ascorbate 
supplementation alters TET2 activity and TAM phenotype. However, it also highlighted the 
limitations of the in vitro melanoma model used, and future studies would aim to develop a bi-
directional model to study TAM phenotype and function in melanoma, and how ascorbate 
















Appendix 1 – Ascorbate Measurement by High-Performance Liquid Chromatography 
(HPLC)  


































Figure 1.1.1: Standard Curve for the Measurement of Ascorbate. Generated by Dr. Juliet Pullar 
through conducting HPLC with known concentrations. The presented slope-intercept equation was 
used to solve for unknown concentrations.   






















Appendix 2 – Immunocytochemistry 




To sort for true surface marker populations, non-specific fluorescence had to be removed from 
the data. This was achieved through using the mean of the associated fluorochrome intensity 
values presented in the IgG control. However, to ensure that positive staining initially existed, 
frequency distributions of the staining intensity values derived from IgG controls and surface 
marker stained cells were overlaid. Figure 2.1.1 serves as an example of this, indicating that 









Figure 2.1.1: Sorting for True CD14+ and CD68+ Monocytes/Macrophages from the Total 
Population of a Day Seven Culture. Frequency distributions of staining intensity values derived from 
IgG control and CD14 or CD68 stained from cells cultured with 20% (v/v) NZM40 conditioned 
media with ascorbate supplementation, were overlaid. 
 
 
















































While non-specific fluorescence could be filtered from the data using the fluorescence 
intensities presented in the blue (nucleus) channel, fluorescent saturation could not be removed 
in a similar manner. Therefore, histograms of frequency distribution were created, as observed 
in figure 2.2.1, and in conjunction with plots generated from the Cell profiler pipeline (example 
shown in figure 2.4) maximum intensity thresholds of 300 were set. Any intensities found 


























































Figure 2.2.1: Frequency Distribution of CD206 Intensity on Cells Cultured with 20% (v/v) 
NZM40 Conditioned Media. Frequency distribution tests were conducted, with values being 
assigned to bins that  reflect the range of data, and the number of values in each bin is shown.    
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Appendix 3 – Normality Tests 












Figure 3.1.1 provides an example of a frequency distribution test, displayed as a histogram. In 
conjunction with the Shapiro-Wilks test, frequency distributions can provide confirmation of 










Figure 3.1.1: Histograms of Normality for IL-10 and CCL-3 Expression in Cells Cultured with MCSF 
+ LPS + IFN-𝛾 Media. Frequency distribution tests were conducted, where the values were assigned 
to bins reflecting the range of data and the number of values in each bin is shown.   









































Appendix 4 -  Gene Expression Measurement 










MCSF 12.11 62.5 50 
MCSF + LPS + IFN-𝛾 10.33 62.5 50 
MCSF + IL-4 + IL-13 10.54 62.5 50 
20% (v/v) NZM40 9.73 62.5 50 
20% (v/v) NZM40 + Asc 10.07 62.5 50 



















400 1 1st 13.29 62.5 30 
400 2 1st 31.98 62.5 30 
700 1 1st 23.79 62.5 30 
      
400 1 2nd 29.98 62.5 30 
400 2 2nd 11.91 62.5 30 
700 1 2nd 13.84 62.5 30 
      
400 1 3rd 10.67 62.5 50 
400 2 3rd 13.87 62.5 50 
700 1 3rd 7.19 62.5 50 








Table 4.1.2: Optimisation of DNA Harvesting from Macrophages Grown Under MCSF Media 












MCSF 47.65 50 50 
MCSF + LPS +IFN-𝛾 41.32 50 50 
MCSF + IL-4 + IL-13 37.26 50 50 
20% (v/v) NZM40 43.04 50 50 
20% (v/v) NZM40 + Asc 37.33 50 50 














400 1 1st 103.1 50 50 
400 2 1st 111.4 50 50 
700 1 1st 66.41 50 50 
      
400 1 2nd 10.21 50 50 
400 2 2nd 35.42 50 50 
700 1 2nd 20.97 50 50 
Abbreviations: ng/𝜇L: Nanograms per microlitre. 
 
Yields from DNA/RNA extraction revealed by the Nanodrop were below desirable, neither 
RNA or DNA extractions achieving the 50ng/𝜇L or 62.5ng/𝜇L targets, respectively, as shown 
within table 4.1.1 and table 4.1.3. With these values, the robustness of downstream targets 
may be impacted. To improve yields, multiple variables were trialed, including increasing the 
lysis volume to either 400𝜇L or 700𝜇L, combining wells and prewarming the elution solution 
to 37℃. The resultant yields and associated trialed variables can be found within table 4.1.2 
and table 4.1.4. While combining wells with 400𝜇L of lysis solution produced the greatest 
yield, there is a greater cost of resources. Therefore, 400𝜇L of lysis solution with no 
combination of wells was selected for downstream experiments, as it produced acceptable 
yields with a lower cost of resources, increasing the benefit:cost ratio.  
 
Table 4.1.3: RNA Harvesting from Macrophages Grown Under Different Experimental Conditions 
Table 4.1.4: Optimisation of RNA Harvesting from Macrophages Grown Under MCSF Media 
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4.2.  Concentration of RNA 
 




Before Conc.    
MCSF         41.26 
 
50 50 
MCSF + LPS +IFN-𝛾 47.06 50 50 
MCSF + IL-4 + IL-13 45.81 50 50 
20% (v/v) NZM40 26.53 50 50 
20% (v/v) NZM40 + Asc 20.44 50 50 
    
After Conc.     
MCSF 123.40 50 12 
MCSF + LPS +IFN-𝛾 117.20 50 12 
MCSF + IL-4 + IL-13 135.70 50 12 
20% (v/v) NZM40 84.07 50 12 
20% (v/v) NZM40 + Asc 62.30 50 12 
Abbreviations: Conc. (ng/𝜇L); concentration (nanogram per microlitre). NZM40; Conditioned 
media. Asc; Ascorbate.  
 
Despite troubleshooting for improving the RNA yield, extraction concentrations for some 
samples continued to fall below the 50ng/𝜇L target. Consequently, RNA was concentrated with 
a speed-vacuum centrifuge (section 2.7). The resultant concentrations surpassed the target 
yields (e.g., table 4.2.1), with concentrations typically increased by three-fold. Therefore, if 
necessary, RNA was concentrated before cDNA synthesis.    








Table 4.2.1: Concentration of Extracted RNA for cDNA Synthesis  
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With previous extracted RNA, supplied by Dr. Abel Ang using a Trizol-based protocol, cDNA 
was generated and primers were tested on a selection of genes. Gel electrophoresis was 
performed to visually observe resultant PCR products. As shown in figure 4.3.1 A, the primers 
were successful in amplifying the provided cDNA, evident by the presence of bands at the 
expected size. However, ARG1 and IL-12𝛽 presented an array of bands, indicating possible 
genomic contamination. To minimalize downstream genomic contamination, the additional 
DNase step in the Quick-DNA/RNATM Miniprep Plus kit protocol was added to the protocol. 
The resultant PCR products can be observed in figure 4.3.1 B, which reflect the lack of 
genomic contamination. However, amplification did not occur successfully for all genes and 
associated conditions, and as well as the gene PCR product, e.g., TGF𝛽1, primer dimers can 
be observed. After multiple trials, primers shown in table 4.3.1 were identified as being 
ineffective for stimulating cDNA amplification, and were replaced with new primer sequences 
as detailed in table 4.3.2. To address the formation of primer dimers, annealing temperature 
during RT-qPCR was increased from 58℃ to 60℃ and primer concentration was reduced from 
2M to 1𝜇M. However, neither variable resulted in the removal of primer dimers, and a lack of 
product arose from the reduced primer concentration, despite the inclusion of template (figure 
4.3.1 C). With repeats showing similar results, primer concentration was retained at 1𝜇M and 
Figure 4.3.1: Gel Electrophoresis Primer Testing for Downstream Gene Expression Measurement. A: Bands 
show PCR products, generated from cDNA derived from Trizol extracted RNA, harvested from cells 
cultured with MCSF media. Old primers were used for cDNA amplification and the PCR annealing 
temperature was 58℃. B: Bands reflect PCR product, generated from cDNA derived from Quick-
DNA/RNATM Miniprep Plus Kit extracted RNA, harvested from cells cultured under different experimental 
conditions. Both A and B utilized primers from table 11 and 12, and PCR reactions had an annealing 
temperature of 58℃. C: Bands show PCR products derived from 2𝜇M and 1𝜇M primer concentrations and 
an annealing temperature of 60℃. Primers from table 11 and 12 were utilized and RNA was isolated from 
cells cultured with different experimental conditions by the DNA/RNA extraction kit. D: Bands reflect PCR 
products amplified with primers from table 12, with an annealing temperature of 60℃ and RNA harvested 
by the DNA/RNA extraction kit, from cells cultured under positive control conditions. Annotations: MC; 
MCSF. L+I; MCSF + LPS + IFN𝛾. 4+13; MCSF + IL-4 + IL-13. Con; 20% (v/v) NZM40 conditioned media. 
Con+A; 20% (v/v) NZM40 conditioned media + 100𝜇M ascorbate. NT; no-template control.         
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the annealing temperature remained at 60℃. Subsequently, all primers that are listed in table 
4.3.2, both new primers and those that were initially found to be effective, were trialed. The 
resultant PCR products (figure 4.3.1 D) guided selection of the final gene panel, providing 
reason for the removal of genes through the lack of product or presence of weak bands and/or 
primer dimers. Considerations of the final gene panel used were also made bearing in mind the 















Forward Primer Reverse Primer Source 
MRC1 121 AGCCAACACCAGCTCCTCAAGA CAAAACGCTCGCGCATTGTCCA Origene 
TFG-𝛽1 122 TACCTGAACCCGTGTTGCTCTC GTTGCTGAGGTATCGCCAGGAA Origene 
IL10 126 TCTCCGAGATGCCTTCAGCAGA TCAGACAAGGCTTGGCAACCCA Origene 
IL-1𝛽 131 CCACAGACCTTCCAGGAGAATG GTGCAGTTCAGTGATCGTACAGG Origene 
TNF-𝛼 135 CTCTTCTGCCTGCTGCACTTTG ATGGGCTACAGGCTTGTCACTC Origene 
IL-12𝛽 98 GACATTCTGCGTTCAGGTCCAG CATTTTTGCGGCAGATGACCGTG Origene 
MMP-9 125 GCCACTACTGTGCCTTTGAGTC CCCTCAGAGAATCGCCAGTACT Origene 
TET2 118 GCTTACCGAGACGCTGAGGAAA AGAGAAGGAGGCACCACAGGTT Origene 
TET3 154 CCACAAGGACCAGCATAACCTC CTCGCTACCAAACTCATCCGTG Origene 
ARG1 130 TCATCTGGGTGGATGCTCACAC GAGAATCCTGGCACATCGGGAA Origene 
iNOS2 136 GCTCTACACCTCCAATGTGACC CTGCCGAGATTTGAGCCTCATG Origene 
VEGF- 𝛼 126 TTGCCTTGCTGCTCTACCTCCA GATGGCAGTAGCTGCGCTGATA Origene 
Table 4.3.1: Genes and Associated Primer Sequences that were Ineffective for the Analysis of Gene Expression and 
Replaced with New Primer Sequences 











Forward Primer Reverse Primer Source 




173 CAAGTGGACATCAACGGGTTC TCCGTGGAGCTGAAGCAATAG NIH Primer 
Blast 
IL10 175 GGCACCCAGTCTGAGAACAG GGCAACCCAGGTAACCCTTA NIH Primer 
Blast 
IL-1𝛽 116 AGCCATGGCAGAAGTACCTG CCTGGAAGGAGCACTTCATCT NIH Primer 
Blast 
TNF-𝛼 189 TCTCCTTCCTGATCGTGGCA CAGCTTGAGGGTTTGCTACAAC NIH Primer 
Blast 
IL-12𝛽 112 CGGTCATCTGCCGCAAAAAT TCCTGGATCAGAACCTAACTGC NIH Primer 
Blast 





MMP-9 177 CGCAGACATCGTCATCCAGT AACCGAGTTGGAACCACGAC NIH Primer 
Blast 
TET2 100 AGCAAGATGGCTGCCCTTTA AATGTTTGCCAGCCTCGTTC NIH Primer 
Blast 
TET3 203 AGTGAGTCCCAACTCCGAGG CCAGCCTTTATTTCCACCTCCT NIH Primer 
Blast 
IL-6 289 CTGCTCCTGGTGTTGCCTG TCACCAGGCAAGTCTCCTCA NIH Primer 
Blast 
CD163 147 AAAAAGCCACAACAGGTCGC CTCTTGAGGAAACTGCAAGCC NIH Primer 
Blast 
CCL3 159 GCTCTCTGCAACCAGTTCTCT TCGCTTGGTTAGGAAGATGACA NIH Primer 
Blast 
ARG1 168 TGGACCCTGGGGAACACTAC GGTCCAGTCCGTCAACATCA NIH Primer 
Blast 
iNOS2 168 GCTTTGTGCGGAATGCCAG CAAACACCAAGGTCATGCGG NIH Primer 
Blast 
VEGFA N/A TTGCCTTGCTGCTCTACCTCCA GATGGCAGTAGCTGCGCTGATA NIH Primer 
Blast 





B-actin 184 GCCGCCAGCTCACCAT TCGTCGCCCACATAGGAATC NIH Primer 
Blast 





Table 4.3.2: Genes and Associated Primer Sequences that were Replaced or Deemed Effective for the 
Analysis of Gene Expression  
*; size for rRNA. N/A; The primers were designed bind/amplify all 7 variants of the gene products.  
Abbreviation: Bp; Base pair. 
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Figure 4.4.1: Analysis of RT-qPCR Gene cDNA Amplification. A: Gel electrophoresis with bleach was 
performed on from Quick-DNA/RNATM Miniprep Plus Kit extracted RNA, harvested from cells grown under 
different experimental conditions. The gel shows bands for each tested condition, representing ribosomal 
RNA 28S, 18S and 5.8S/5S, which are highlighted by the blue arrows. B: Gel electrophoresis was conducted 
on Quick- DNA/RNATM Miniprep Plus Kit extracted RNA, harvested from cells grown under different 
experimental conditions. The gel shows the presence or lack of bands for each gene and associated condition, 
representing the generated PCR products. C and D: Melting curves were derived and analyzed with the 
LightCyclerâ 480 SW 1.5.1 software. C shows an acceptable melting curve, while D reflects an unacceptable 
curve.  Annotations: MC; MCSF. L+I; MCSF + LPS + IFN-𝛾. 4+13; MCSF + IL-4 + IL-13. Con; 20% (v/v) 
NZM40 conditioned media. Con+A; 20% (v/v) NZM40 conditioned media + 100𝜇M ascorbate. NT; no-










































Analysis of the PCR melting curves on LightCyclerâ 480 SW 1.5.1 software, revealed that 
some of the output data was not clean. As this would impact CT values, the poor-quality data 
had to be removed. An example of an acceptable and unacceptable melting curve can be found 
in figure 4.4.1 C and D, respectively, with the presence of multiple curves and/or curves with 
large areas indicating non-specific amplification within the reaction. To ensure that these 
amplifications were not the result of degrading RNA, RNA integrity was tested. As observed 
in figure 4.4.1 A, bands correlating to 28S, 18S and 5.8/5S ribosomal RNA were produced. 
These bands are relatively clean, with some smear, indicating RNA degradation, but not at 
substantial levels. This could provide an explanation for random amplifications or the lack of 
amplification from some primers, but due to time constrictions, troubleshooting for these non-
specific amplifications could not continue.   
 
Due to the presence of poor melting curves for some PCR reactions, PCR products were 
subjected to gel electrophoresis. The gels (e.g., figure 4.4.1 B) were used in conjunction with 
melting curve analysis to filter poor from acceptable PCR reactions. For example, as observed 
within figure 4.4.1 B, VEGF𝐴 expression from cells grown under 20% (v/v) NZM40 
conditioned media, is represented by a relatively strong gene product band and primer dimer. 
Due to the similarity in presence, and with the melting curve containing several peaks, the data 
was discarded, as the primer dimer would have impacted the CT value. Using this conjugated 








Appendix 5 – Analysis of Epigenetic Markers by Mass Spectrometry 
5.1.  Concentration of DNA 
 




Before Conc.     
MCSF 1st 13.95 62.5 100 
MCSF + LPS +IFN-𝛾 1st 20.43 62.5 100 
MCSF + IL-4 + IL-13 1st 21.09 62.5 100 
20% (v/v) NZM40 1st 18.43 62.5 100 
20% (v/v) NZM40 + Asc 1st 10.38 62.5 100 
     
MCSF 2nd 13.04 62.5 100 
MCSF + LPS +IFN-𝛾 2nd 13.40 62.5 100 
MCSF + IL-4 + IL-13 2nd 14.45 62.5 100 
20% (v/v) NZM40 2nd 12.93 62.5 100 
20% (v/v) NZM40 + Asc 2nd 9.58 62.5 100 
     
After Conc.      
MCSF Combined 38.98 62.5 18 
MCSF + LPS +IFN-𝛾 Combined 50.55 62.5 18 
MCSF + IL-4 + IL-13 Combined 92.51 62.5 18 
20% (v/v) NZM40 Combined 79.98 62.5 18 
20% (v/v) NZM40 + Asc Combined 50.91 62.5 18 
Abbreviations: Conc. (ng/𝜇L); concentration (nanogram per microlitre). NZM40; Conditioned 
media. Asc; Ascorbate.  
 
Because DNA extractions continued to fall below the 62.5ng/𝜇L target, DNA was concentrated 
with a speed-vacuum centrifuge (section 2.7). While this improved the concentration, only 
some samples surpassed the target concentration, as shown in table 5.1.1. Nevertheless, DNA 






Table 5.1.1: Concentration of Extracted DNA for Mass Spectrometry  
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Figure 5.2.1: Standard Curve for the Measurement of Epigenetic Markers. Created by Dr. Nick Magon 
through conducting mass spectrometry on known standards. Standard curves were generated for the 
presence of deoxycytidine, methylcytidine and hydroxymethylcytidine in DNA. The presented slope-
intercept equations were used to solve for unknown concentrations.  







































y = 6x - 0.0054
R2 =0 .9957













































y = 0.2x - 0.0633
R² = 0.9941





































Appendix 6 – Monocyte/Macrophage Growth with NZM Cell Lines  
6.1.  Transcriptomic Data for the NZM Melanoma Cell Lines   
 
Genes NZM9 NZM40 NZM42 
CSF1 5.786 19.889 1.116 
CSF2 0.834 2.542 0 
TET2 0.175 0.358 0.377 
IL4 0 0 0 
IL13 0 0.004 0.004 
IL10 0 0.011 0 
TGF𝛽1 12.838 21.956 2.457 
IFN𝛾 0 0 0 
IL34 0.010 0.055 0.037 
CCL2 0.010 0.455 0.117 
Transcriptomic data provided by Professor Bruce Baguley (University of Auckland, NZ) 
































Table 6.1.1: Gene Expression Levels (FPKM) in Melanoma Cells Lines 
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Appendix 7 – Quality of RNA Extract  
7.1.  Organic Contamination in Extracted RNA 
 
 Conc. (ng/𝝁L) 260/280 230/260 
MCSF 123.40 2.15 0.22 
MCSF + LPS +IFN-𝛾 117.20 2.11 0.87 
MCSF + IL-4 + IL-13 135.70 2.07 1.61 
20% (v/v) NZM40 84.07 1.97 1.59 
20% (v/v) NZM40 + Asc 62.30 1.96 1.06 
Abbreviations: Conc. (ng/𝜇L); concentration (nanogram per microlitre). NZM40; Conditioned 
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